

Fatal Toxic Effects Associated With Immune Checkpoint

JAMA Oncology

4, 1721

DOI: [10.1001/jamaoncol.2018.3923](https://doi.org/10.1001/jamaoncol.2018.3923)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Immune checkpoint inhibitors: fatal toxic effects. <i>Reactions Weekly</i> , 2018, 1721, 8-8.	0.0	3
2	Arterial events in cancer patients—the case of acute coronary thrombosis. <i>Journal of Thoracic Disease</i> , 2018, 10, S4367-S4385.	0.6	31
4	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. <i>Lancet Oncology</i> , The, 2018, 19, 1579-1589.	5.1	742
5	Updates on Immunotherapy for the Treatment of Skin Cancer. <i>Current Dermatology Reports</i> , 2018, 7, 311-320.	1.1	2
7	Insights into the risk of fatal AEs with ICIs. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 653-653.	12.5	0
8	Immunotherapy Adverse Events: An Emergency Nursing Perspective. <i>Journal of Emergency Nursing</i> , 2019, 45, 699-706.	0.5	1
9	Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 872-884.	1.9	31
10	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. <i>Radiology</i> , 2019, 293, 15-29.	3.6	45
11	A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-6.	0.2	8
12	The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma. <i>Melanoma Management</i> , 2019, 6, MMT16.	0.1	2
13	Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view. <i>Life Sciences</i> , 2019, 233, 116713.	2.0	42
14	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. <i>Future Oncology</i> , 2019, 15, 2743-2757.	1.1	7
15	Clinical significance of signs of autoimmune colitis in ¹⁸ F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. <i>Immunotherapy</i> , 2019, 11, 667-676.	1.0	41
16	Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 588-596.	0.4	43
18	Diagnosis of immune checkpoint inhibitor-associated myocarditis: A systematic review. <i>International Journal of Cardiology</i> , 2019, 296, 113-121.	0.8	34
19	Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications. <i>Liver International</i> , 2019, 39, 1608-1621.	1.9	67
20	Immune-Related Adverse Events: A Case-Based Approach. <i>Frontiers in Oncology</i> , 2019, 9, 530.	1.3	31
21	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. <i>Nature Medicine</i> , 2019, 25, 1243-1250.	15.2	133

#	ARTICLE	IF	CITATIONS
22	Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer. <i>European Urology</i> , 2019, 76, 524-532.	0.9	38
23	Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 800-808.	1.9	60
24	Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1865-1878.	1.4	49
25	Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population. <i>Melanoma Management</i> , 2019, 6, MMT13.	0.1	13
26	Germinal immunogenetics as a predictive factor for immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 146-152.	2.0	5
27	Nivolumab-induced celiac-like enteropathy in patient with metastatic renal cell carcinoma: Case report and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 1689-1693.	0.2	8
28	Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. <i>ESMO Open</i> , 2019, 4, e000472.	2.0	26
29	Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 972.	1.3	17
30	Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives. <i>Cancers</i> , 2019, 11, 1420.	1.7	9
31	Comparison of drug safety data obtained from the monitoring system, literature, and social media: An empirical proof from a Chinese patent medicine. <i>PLoS ONE</i> , 2019, 14, e0222077.	1.1	4
32	The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials. <i>International Immunopharmacology</i> , 2019, 77, 105975.	1.7	7
33	Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. , 2019, 7, 286.		92
34	Pancreatic cancer-educated macrophages protect cancer cells from complement-dependent cytotoxicity by up-regulation of CD59. <i>Cell Death and Disease</i> , 2019, 10, 836.	2.7	29
35	Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. <i>Journal of Oncology Practice</i> , 2019, 15, e825-e834.	2.5	37
36	Small molecules as theranostic agents in cancer immunology. <i>Theranostics</i> , 2019, 9, 7849-7871.	4.6	42
37	Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1254.	1.6	21
38	Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy. <i>Critical Reviews in Immunology</i> , 2019, 39, 93-103.	1.0	16
39	A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. <i>Cancers</i> , 2019, 11, 1782.	1.7	53

#	ARTICLE	IF	CITATIONS
40	Emerging agents and regimens for hepatocellular carcinoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 110.	6.9	71
41	Effect Modification of Vitamin D Supplementation by Histopathological Characteristics on Survival of Patients with Digestive Tract Cancer: Post Hoc Analysis of the AMATERASU Randomized Clinical Trial. <i>Nutrients</i> , 2019, 11, 2547.	1.7	12
42	Study on the Rule of Concrete Corrosion in Harsh Environment. <i>IOP Conference Series: Earth and Environmental Science</i> , 2019, 304, 052002.	0.2	1
43	Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. <i>Journal of Neuro-Oncology</i> , 2019, 145, 1-9.	1.4	69
45	Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?. <i>Annals of Intensive Care</i> , 2019, 9, 25.	2.2	46
46	The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers. <i>Cancer Treatment Reviews</i> , 2019, 79, 101887.	3.4	49
47	Differences in clinical presentation and outcome between immune checkpoint inhibitor-associated myocarditis and classical acute myocarditis: Same disease, distinct challenges to face. <i>International Journal of Cardiology</i> , 2019, 296, 124-126.	0.8	9
48	Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2019, 2, e1911519.	2.8	57
49	Cardiotoxicity from immune checkpoint inhibitors. <i>IJC Heart and Vasculature</i> , 2019, 25, 100420.	0.6	79
50	Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, e31-e43.	2.5	97
51	Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma. <i>Experimental Hematology and Oncology</i> , 2019, 8, 20.	2.0	4
52	Imaging of myocarditis and inflammatory cardiomyopathies. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 630-641.	0.7	21
53	Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases. <i>Journal of Autoimmunity</i> , 2019, 104, 102333.	3.0	70
54	Cerebrospinal fluid lymphocytosis: a hallmark of neurological complications during checkpoint inhibition. <i>European Journal of Cancer</i> , 2019, 121, 1-3.	1.3	2
55	Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses. <i>Molecular Therapy</i> , 2019, 27, 1892-1905.	3.7	28
56	Immune checkpoint inhibitor-related luminal GI adverse events. <i>Gastrointestinal Endoscopy</i> , 2019, 90, 881-892.	0.5	24
57	Acute and Long-term Adverse Events Associated With Checkpoint Blockade. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150926.	0.7	7
58	Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 905-912.	1.3	78

#	ARTICLE	IF	CITATIONS
59	ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 765-774.	1.2	35
60	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019, 115, 854-868.	1.8	311
61	Success of immune checkpoint blockade therapies – mechanisms and implications for hepatology. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, 74-86.	0.2	2
62	<p>Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3957-3969.	0.9	5
63	Treatment Outcomes of Immune-Related Cutaneous Adverse Events. <i>Journal of Clinical Oncology</i> , 2019, 37, 2746-2758.	0.8	160
64	Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 32.	0.4	42
65	Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients. <i>Cardiac Failure Review</i> , 2019, 5, 112-118.	1.2	39
66	Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. <i>International Journal of Cardiology</i> , 2019, 292, 171-179.	0.8	44
67	Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. <i>Intensive Care Medicine</i> , 2019, 45, 988-997.	3.9	18
68	Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e120-e120.	0.5	15
69	Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. , 2019, 7, 134.		237
70	Approaches to High-Risk Resected Stage II and III Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e207-e211.	1.8	18
71	Immunotherapy in Older Adults with Cancer. <i>Current Oncology Reports</i> , 2019, 21, 56.	1.8	16
72	Immunotherapy in Older Adults: A Checkpoint to Palliation?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e110-e120.	1.8	11
73	The promise of Immuno-oncology: implications for defining the value of cancer treatment. , 2019, 7, 129.		66
74	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 563-580.	12.5	1,235
75	The 2018 Nobel Prize in Medicine for breakthroughs in targeting immune checkpoint inhibitors: a brief perspective. <i>Antibody Therapeutics</i> , 2019, 2, 40-43.	1.2	2
76	Immune Checkpoint Inhibitor-Associated Pericarditis. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1102-1108.	0.5	72

#	ARTICLE	IF	CITATIONS
77	Managing cardiotoxicity associated with immune checkpoint inhibitors. <i>Chronic Diseases and Translational Medicine</i> , 2019, 5, 6-14.	0.9	52
78	Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. <i>Trends in Immunology</i> , 2019, 40, 511-523.	2.9	180
79	Expanding Therapeutic Options for Older Adults: Case-Based Updates in Breast and Lung Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1012-1019.	1.3	2
80	Management of immune related adverse events induced by immune checkpoint inhibition. <i>Cancer Letters</i> , 2019, 456, 80-87.	3.2	36
81	Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 393-404.	1.1	26
82	Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. <i>Cancers</i> , 2019, 11, 305.	1.7	51
83	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 884-896.	0.6	78
84	Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading. <i>Current Treatment Options in Oncology</i> , 2019, 20, 35.	1.3	44
85	Immunotherapy for small cell lung cancer: mechanisms of resistance. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 423-432.	1.4	53
87	Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent <i>Clostridium Difficile</i> Infection. <i>Case Reports in Oncology</i> , 2019, 12, 164-170.	0.3	15
88	Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. <i>Targeted Oncology</i> , 2019, 14, 205-221.	1.7	72
89	Adverse events 2.0—Let us get SERIOs. <i>European Journal of Cancer</i> , 2019, 112, 29-31.	1.3	19
90	Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1. <i>Nano Letters</i> , 2019, 19, 2935-2944.	4.5	134
91	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 867-875.	0.8	258
92	<p>Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients<p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 211-221.	0.9	42
93	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 563-574.	2.0	51
94	Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 457-467.	1.4	7
95	Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?. <i>Oncologist</i> , 2019, 24, e1148-e1155.	1.9	81

#	ARTICLE	IF	CITATIONS
96	Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. <i>Oncologist</i> , 2019, 24, e1228-e1231.	1.9	30
97	Anti-“PD-1” Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients. <i>Cancer Immunology Research</i> , 2019, 7, 1755-1759.	1.6	20
98	Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy. <i>Oncologist</i> , 2019, 24, 872-876.	1.9	38
99	Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481988419.	1.4	62
100	Combination Nivolumab/Ipilimumab Immunotherapy For Melanoma With Subsequent Unexpected Cardiac Arrest: A Case Report and Review of Literature. <i>Journal of Immunotherapy</i> , 2019, 42, 313-317.	1.2	11
101	Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1331-1340.	2.1	49
102	Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 1300.	1.6	12
103	Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. , 2019, 7, 341.		126
104	Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 272-289.	0.6	2
105	Checkpoint Inhibitor-Associated Autoimmunity. <i>Journal of Clinical Rheumatology</i> , 2019, Publish Ahead of Print, .	0.5	0
106	Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1350.	1.6	75
107	Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019, 28, 190058.	3.0	73
108	Developing neoantigen-targeted T cell-based treatments for solid tumors. <i>Nature Medicine</i> , 2019, 25, 1488-1499.	15.2	173
109	Immune checkpoint inhibitors. <i>Current Opinion in Ophthalmology</i> , 2019, 30, 426-433.	1.3	8
110	Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?. <i>Clinical Cancer Research</i> , 2019, 25, 1452-1454.	3.2	33
111	Dramatic response of nivolumab-associated psoriasiform dermatitis to etoposide. <i>European Journal of Cancer</i> , 2019, 107, 97-99.	1.3	12
112	Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. <i>Drug Safety</i> , 2019, 42, 281-294.	1.4	69
113	New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. <i>Lancet Oncology</i> , The, 2019, 20, e54-e64.	5.1	149

#	ARTICLE	IF	CITATIONS
114	Analysis for Science Librarians of the 2018 Nobel Prize in Physiology or Medicine: The Life and Work of James P. Allison and Tasuku Honjo. <i>Science and Technology Libraries</i> , 2019, 38, 1-29.	0.8	0
115	Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 511-521.	1.2	153
116	Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 133-140.	0.5	1
117	Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors. <i>Investigational New Drugs</i> , 2020, 38, 160-171.	1.2	30
118	Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. <i>Seminars in Cancer Biology</i> , 2020, 64, 93-101.	4.3	135
119	Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. <i>Journal of Rheumatology</i> , 2020, 47, 166-175.	1.0	47
120	Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. <i>Histopathology</i> , 2020, 76, 233-243.	1.6	66
121	Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer. <i>European Urology</i> , 2020, 77, 299-308.	0.9	38
122	Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma. <i>Clinical Lung Cancer</i> , 2020, 21, e74-e77.	1.1	16
123	Principles of Immunotherapy in Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 161-173.	0.5	28
124	Interaction and assembly processes of abundant and rare microbial communities during a diatom bloom process. <i>Environmental Microbiology</i> , 2020, 22, 1707-1719.	1.8	60
126	Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 322-328.	2.0	13
127	Something old, something new: liver injury associated with total parenteral nutrition therapy and immune checkpoint inhibitors. <i>Human Pathology</i> , 2020, 96, 39-47.	1.1	17
128	Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment. <i>Lung Cancer</i> , 2020, 140, 116-117.	0.9	3
129	Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. <i>Journal of Virology</i> , 2020, 94, .	1.5	54
130	Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. <i>Lancet Oncology</i> , The, 2020, 21, e55-e65.	5.1	59
131	Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors. <i>Investigational New Drugs</i> , 2020, 38, 1200-1206.	1.2	52
132	Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event. <i>Canadian Journal of Cardiology</i> , 2020, 36, 476-481.	0.8	40

#	ARTICLE	IF	CITATIONS
133	Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher. <i>Oral Oncology</i> , 2020, 101, 104492.	0.8	44
134	Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer. <i>Critical Care Medicine</i> , 2020, 48, 10-21.	0.4	42
135	Immune-checkpoint inhibitors induced diarrhea and colitis. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 25-32.	1.0	21
136	Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy</i> , 2020, 43, 1-7.	1.2	75
137	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.	0.8	135
138	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. <i>Oncologist</i> , 2020, 25, e398-e404.	1.9	10
139	Drug-Induced Liver Injury in the Setting of Chronic Liver Disease. <i>Clinics in Liver Disease</i> , 2020, 24, 89-106.	1.0	13
140	Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges. <i>Life Sciences</i> , 2020, 240, 117093.	2.0	12
141	Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. <i>Thoracic Cancer</i> , 2020, 11, 475-480.	0.8	9
142	Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 291-298.	0.7	21
143	Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7195.	1.8	55
144	Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy. <i>Cancer Immunology Research</i> , 2020, 8, 1230-1235.	1.6	10
145	Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice. <i>Current Opinion in Oncology</i> , 2020, 32, 603-612.	1.1	5
146	Atezolizumab-Induced Bell's Palsy in a Patient With Small Cell Lung Cancer. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2020, 8, 232470962096501.	0.3	3
147	Application and Prospects of Molecular Imaging in Immunotherapy. <i>Cancer Management and Research</i> , 2020, Volume 12, 9389-9403.	0.9	8
148	Landscape of immune checkpoint inhibitor-related adverse events in Chinese population. <i>Scientific Reports</i> , 2020, 10, 15567.	1.6	20
149	Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2020, 160, 105194.	3.1	13
150	Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review. <i>Thrombosis Research</i> , 2020, 196, 444-453.	0.8	55

#	ARTICLE	IF	CITATIONS
151	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
152	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1435-1448.	0.6	132
153	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. <i>JHEP Reports</i> , 2020, 2, 100170.	2.6	86
154	Nivolumab-Induced Thrombotic Thrombocytopenic Purpura in a Patient with Anal Squamous Cell Carcinoma: A Lesson on Hematologic Toxicity from Immunotherapy. <i>Oncologist</i> , 2020, 25, 1009-1012.	1.9	10
155	Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. <i>European Journal of Cancer</i> , 2020, 138, 125-132.	1.3	44
156	Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. <i>Nature Communications</i> , 2020, 11, 4946.	5.8	120
157	Emergency management of immune-related toxicity. <i>Current Opinion in Oncology</i> , 2020, 32, 274-281.	1.1	5
158	Uses of pharmacovigilance databases: An overview. <i>Therapie</i> , 2020, 75, 591-598.	0.6	92
159	Fatal Cholestatic Liver Injury during Treatment with PD1 Immune Checkpoint Inhibitor for Malignant Melanoma: A Case Report. <i>Case Reports in Oncology</i> , 2020, 13, 659-663.	0.3	15
160	A Review of the Mechanisms and Clinical Implications of Precision Cancer Therapyâ€Related Toxicity: A Primer for the Radiologist. <i>American Journal of Roentgenology</i> , 2020, 215, 770-780.	1.0	4
161	Immunotherapies and Combination Strategies for Immuno-Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5009.	1.8	63
162	Insights from Pharmacovigilance: Gastrointestinal-Related Immune Checkpoint Inhibitor Adverse Events. <i>Gastroenterology</i> , 2020, 159, 1195-1200.e1.	0.6	5
163	Malignant cardiac tamponade: safety and efficacy of intrapericardial bleomycin instillation. <i>Acta Clinica Belgica</i> , 2022, 77, 51-58.	0.5	5
164	Durvalumab-Induced Diffuse Alveolar Hemorrhage: An Autopsy Case Report. <i>Case Reports in Oncology</i> , 2020, 13, 696-701.	0.3	7
165	A promising treatment option for refractory male primary choriocarcinoma: report of two cases. <i>Translational Cancer Research</i> , 2020, 9, 3054-3060.	0.4	11
166	Novel systemic therapy for hepatocellular carcinoma. <i>Hepatology International</i> , 2020, 14, 638-651.	1.9	15
167	Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain: a Rapid Review. <i>Journal of General Internal Medicine</i> , 2020, 35, 935-944.	1.3	27
168	Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy. , 2020, 8, e001687.		11

#	ARTICLE	IF	CITATIONS
169	Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 549168.	1.3	9
170	Severe mesenteric ischemia with multiple organ failure in a patient previously treated with a humanized monoclonal antibody against programmed death receptor-1 (pembrolizumab), a case of pembrolizumab associated catastrophic antiphospholipid syndrome?. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2097222.	0.2	5
171	A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2082-2096.	1.3	4
172	The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors. <i>BMC Cancer</i> , 2020, 20, 1128.	1.1	7
173	<p>Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11725-11740.	1.0	25
174	Estimation of US patients with cancer who may respond to cytotoxic chemotherapy. <i>Future Science OA</i> , 2020, 6, FSO600.	0.9	9
175	A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1253-1253.	0.7	3
176	Immune Checkpoint Inhibitor-Related Pneumonitis. <i>Respiration</i> , 2020, 99, 932-942.	1.2	30
177	Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9056.	1.8	19
178	Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. <i>ESMO Open</i> , 2020, 5, e000945.	2.0	14
179	Immunosenescence: a key player in cancer development. <i>Journal of Hematology and Oncology</i> , 2020, 13, 151.	6.9	198
180	Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitorâ€“Associated Myocarditis. <i>Journal of the American Heart Association</i> , 2020, 9, e018306.	1.6	38
181	Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments. <i>Frontiers in Oncology</i> , 2020, 10, 572329.	1.3	7
182	Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors. <i>JACC: CardioOncology</i> , 2020, 2, 511-514.	1.7	8
183	Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094092.	1.4	11
184	MRI Findings of Immune Checkpoint Inhibitorâ€“Induced Hypophysitis: Possible Association with Fibrosis. <i>American Journal of Neuroradiology</i> , 2020, 41, 1683-1689.	1.2	22
185	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <i>Journal of Autoimmunity</i> , 2020, 114, 102514.	3.0	37
186	Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. <i>International Immunopharmacology</i> , 2020, 87, 106770.	1.7	7

#	ARTICLE	IF	CITATIONS
187	Multidisciplinary Approach of Immune Checkpoint Inhibitor-Related Pneumonitis: A Key to Address Knowledge and Management Gaps. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1261-1264.	0.5	6
189	Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data. <i>Cancer Medicine</i> , 2020, 9, 6576-6585.	1.3	21
190	ECG Changes in Melanoma Patients Undergoing Cancer Therapy—Data from the ECoR Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 2060.	1.0	6
191	Pulmonary toxicity of systemic lung cancer therapy. <i>Respirology</i> , 2020, 25, 72-79.	1.3	42
192	Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Pharmacology</i> , 2021, 106, 123-136.	0.9	24
193	SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. <i>Journal of Hematology and Oncology</i> , 2020, 13, 105.	6.9	73
194	Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. <i>Targeted Oncology</i> , 2020, 15, 449-466.	1.7	86
195	Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. <i>Clinical and Experimental Immunology</i> , 2020, 202, 335-352.	1.1	20
196	Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2403-2408.	2.0	10
197	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. <i>Lancet Oncology</i> , 2020, 21, e398-e404.	5.1	74
198	Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2020, 8, 778-778.	0.7	1
199	The efficacy and safety of PD-1/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 3804-3818.	0.4	7
200	A decade of immune-checkpoint inhibitors in cancer therapy. <i>Nature Communications</i> , 2020, 11, 3801.	5.8	920
201	Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa069.	0.1	14
202	Immune checkpoint inhibitor-related cutaneous adverse events. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e149-e153.	0.7	7
203	Immune Oncology Biomarkers in Lung Cancer: an Overview. <i>Current Oncology Reports</i> , 2020, 22, 107.	1.8	8
204	Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report. <i>Immunotherapy</i> , 2020, 12, 1213-1219.	1.0	6
205	COVID-19 and Cardiovascular Health Among Patients with Cancer. <i>Current Cardiology Reports</i> , 2020, 22, 171.	1.3	8

#	ARTICLE	IF	CITATIONS
206	Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 556275.	1.3	6
207	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. <i>Journal of Immunotherapy</i> , 2020, 43, 291-298.	1.2	7
208	How we treat neurological toxicity from immune checkpoint inhibitors. <i>ESMO Open</i> , 2020, 4, e000540.	2.0	25
209	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6159-6173.	1.0	11
210	Hemophagocytic syndrome associated with pembrolizumab therapy successfully controlled by cyclosporin. <i>Journal of Dermatology</i> , 2020, 47, e422-e423.	0.6	2
211	Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis. <i>Immunotherapy</i> , 2020, 12, 1183-1193.	1.0	12
212	Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1279-1294.	0.9	28
213	Exceptional response to nivolumab of a heavily pre-treated patient with metastatic renal-cell cancer: from a case report to molecular investigation and future perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094615.	1.4	0
214	Cardiothoracic Complications of Immune Checkpoint Inhibitor Therapy: An Imaging Review. <i>Journal of Computer Assisted Tomography</i> , 2020, 44, 652-655.	0.5	2
215	Immune Related Adverse Events. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 432-440.	1.0	4
217	Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review. <i>Thoracic Cancer</i> , 2020, 11, 2916-2923.	0.8	7
218	Nucleic Acid-Based Approaches for Tumor Therapy. <i>Cells</i> , 2020, 9, 2061.	1.8	40
219	Systemic treatment of advanced/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3075-3078.	1.2	4
220	Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 554313.	1.3	32
221	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. <i>Supportive Care in Cancer</i> , 2020, 28, 6145-6157.	1.0	14
222	COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy. <i>Immunotherapy</i> , 2020, 12, 1133-1138.	1.0	10
223	Concomitant development of neurologic and cardiac immune-related adverse effects in patients treated with immune checkpoint inhibitors for melanoma. <i>Melanoma Research</i> , 2020, 30, 484-491.	0.6	10
224	ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4208-e4218.	1.8	15

#	ARTICLE	IF	CITATIONS
225	Cardio-Oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 480-504.	157.7	29
226	Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 1637-1659.	0.4	17
227	New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091380.	1.4	10
228	<p></p>A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6493-6509.	0.9	19
229	Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2. <i>Frontiers in Oncology</i> , 2020, 10, 1555.	1.3	5
230	Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5774.	1.8	23
231	Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. <i>ESMO Open</i> , 2020, 5, e000866.	2.0	34
232	Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review. <i>Cells</i> , 2020, 9, 1896.	1.8	73
233	Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis. , 2020, 8, e001887.		45
234	Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm. <i>Frontiers in Oncology</i> , 2020, 10, 583781.	1.3	6
235	By Releasing the Brakes With Immunotherapy, Are We Accelerating Atherosclerosis?. <i>Circulation</i> , 2020, 142, 2312-2315.	1.6	9
236	The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 284.	3.5	67
237	Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature. <i>Frontiers in Neurology</i> , 2020, 11, 538695.	1.1	37
238	Strategies for improving the management of immune-related adverse events. , 2020, 8, e001754.		60
239	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 541-547.	0.1	0
240	Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. , 2020, 8, e001488.		22
241	Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	0.9	13
242	Fulminant myocarditis: a comprehensive review from etiology to treatments and outcomes. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 287.	7.1	72

#	ARTICLE	IF	CITATIONS
243	Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. <i>Annals of Translational Medicine</i> , 2020, 8, 1095-1095.	0.7	27
244	Efficacy of Nivolumab Plus Ipilimumab in a Patient With Renal Cell Carcinoma Concomitant With Cardiac Metastasis: A Case Report. <i>In Vivo</i> , 2020, 34, 1475-1480.	0.6	4
245	Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma. <i>International Ophthalmology Clinics</i> , 2020, 60, 77-89.	0.3	7
246	Cardiotoxicity danger in immunotherapy. <i>IUBMB Life</i> , 2020, 72, 1160-1167.	1.5	4
247	Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy. <i>Cancer Immunology Research</i> , 2020, 8, 851-855.	1.6	37
248	Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis. <i>Clinical Chemistry</i> , 2020, 66, 779-793.	1.5	74
249	Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. <i>Annals of Oncology</i> , 2020, 31, 1273-1275.	0.6	44
250	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , 2020, 6, 38.	18.1	684
251	Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis. <i>Oncologist</i> , 2020, 25, 696-701.	1.9	73
252	Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019. <i>Hematological Oncology</i> , 2020, 38, 565-575.	0.8	22
253	Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. <i>Journal of Hematology and Oncology</i> , 2020, 13, 47.	6.9	84
254	Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary. <i>Journal of Dermatology</i> , 2020, 47, e237-e239.	0.6	3
255	Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1753-1768.	1.1	7
256	Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2020, 85, 106628.	1.7	14
257	Pulmonary Complications Secondary to Immune Checkpoint Inhibitors. <i>International Journal of Chronic Diseases</i> , 2020, 2020, 1-5.	1.9	1
258	Adjuvant immunotherapy: the sting in the tail. <i>European Journal of Cancer</i> , 2020, 132, 207-210.	1.3	20
259	Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond. <i>Current Oncology Reports</i> , 2020, 22, 56.	1.8	23
260	Immune checkpoint inhibitor-related dermatologic adverse events. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1255-1268.	0.6	221

#	ARTICLE	IF	CITATIONS
261	latrogenesis and neurological manifestations in the elderly. <i>Revue Neurologique</i> , 2020, 176, 710-723.	0.6	4
262	Ear and labyrinth toxicities induced by immune checkpoint inhibitors: a disproportionality analysis from 2014 to 2019. <i>Immunotherapy</i> , 2020, 12, 531-540.	1.0	2
263	COVID-19 and immune checkpoint inhibitors: initial considerations. , 2020, 8, e000933.		45
264	Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma. <i>Cancers</i> , 2020, 12, 1321.	1.7	11
265	A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future. <i>Current Oncology</i> , 2020, 27, 87-97.	0.9	554
266	Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy. <i>New England Journal of Medicine</i> , 2020, 382, 2374-2375.	13.9	54
267	Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system. <i>Herz</i> , 2020, 45, 645-651.	0.4	16
268	Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. <i>Autoimmunity Reviews</i> , 2020, 19, 102586.	2.5	80
269	Immune checkpoint inhibitors-induced autoimmunity: The impact of gender. <i>Autoimmunity Reviews</i> , 2020, 19, 102590.	2.5	37
270	<p>Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4871-4881.	0.9	29
271	Molecular engineering of anti-PD-L1 peptide and photosensitizer for immune checkpoint blockade photodynamic-immunotherapy. <i>Chemical Engineering Journal</i> , 2020, 400, 125995.	6.6	36
272	Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2020, 12, 675-679.	1.0	3
273	Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an update. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 582-609.	0.4	24
274	Pulmonary Complications of Immunotherapy. <i>Clinics in Chest Medicine</i> , 2020, 41, 295-305.	0.8	1
275	Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. , 2020, 8, e000266.		69
276	Clinical significance of tumour mutation burden in immunotherapy across multiple cancer types: an individual meta-analysis. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1023-1031.	0.6	8
277	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. <i>BMC Cancer</i> , 2020, 20, 557.	1.1	29
278	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. <i>Lung Cancer</i> , 2020, 146, 174-181.	0.9	8

#	ARTICLE	IF	CITATIONS
279	Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. , 2020, 8, e000984.		15
280	ADRB3 expression in tumor cells is a poor prognostic factor and promotes proliferation in non-small cell lung carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2345-2355.	2.0	6
281	New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity. <i>Current Oncology Reports</i> , 2020, 22, 65.	1.8	44
282	Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. <i>Frontiers in Pharmacology</i> , 2020, 11, 830.	1.6	21
283	COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination. <i>Brain Sciences</i> , 2020, 10, 345.	1.1	38
284	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. <i>MedComm</i> , 2020, 1, 47-68.	3.1	93
285	Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives. <i>Current Gastroenterology Reports</i> , 2020, 22, 15.	1.1	20
286	Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia. <i>New England Journal of Medicine</i> , 2020, 382, 1150-1159.	13.9	7
287	The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology. <i>BMC Biology</i> , 2020, 18, 29.	1.7	6
288	Marked elevation of creatine phosphokinase alone caused by sintilimab - beware of hypothyroid myopathy. <i>European Journal of Cancer</i> , 2020, 128, 57-59.	1.3	7
289	Prognostic significance of the radiologic features of pneumonitis induced by anti- PD-1 therapy. <i>Cancer Medicine</i> , 2020, 9, 3070-3077.	1.3	17
290	Neurologic complications of immune checkpoint inhibitors. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 479-488.	1.0	82
291	Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach. <i>Internal and Emergency Medicine</i> , 2020, 15, 587-598.	1.0	16
292	Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation. <i>Clinical Immunology</i> , 2020, 213, 108377.	1.4	44
293	Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 197.	1.3	9
294	A Fatal Case of Pembrolizumab-Induced Myocarditis in Non-“Small Cell Lung” Cancer. <i>JACC: Case Reports</i> , 2020, 2, 426-430.	0.3	7
295	Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma. <i>Internal Medicine</i> , 2020, 59, 1075-1080.	0.3	16
296	Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. <i>Current Oncology Reports</i> , 2020, 22, 39.	1.8	199

#	ARTICLE	IF	CITATIONS
297	Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2020, 12, 269-273.	1.0	188
298	Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. <i>Nature Reviews Cardiology</i> , 2020, 17, 474-502.	6.1	332
299	Moving towards personalized treatments of immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 504-515.	12.5	189
300	TGF-beta: a master immune regulator. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 427-438.	1.5	101
301	Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. <i>Immune Network</i> , 2020, 20, e9.	1.6	143
302	Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. <i>Hepatology</i> , 2020, 72, 315-329.	3.6	131
303	The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. <i>European Journal of Cancer</i> , 2020, 130, 39-50.	1.3	37
304	Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 171-177.	1.4	32
305	Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 451-464.	1.6	63
306	Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report. <i>Case Reports in Oncology</i> , 2020, 13, 43-48.	0.3	7
307	Acute Neurological Complications of Brain Tumors and Immune Therapies, a Guideline for the Neuro-hospitalist. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 32.	2.0	0
308	Primary Adrenal Insufficiency during Immune Checkpoint Inhibitor Treatment: Case Reports and Review of the Literature. <i>Case Reports in Oncology</i> , 2020, 13, 621-626.	0.3	16
309	Brain Metastases Unresponsive to Immunotherapy Detected by 18F-FDG-PET/CT in a Patient with Melanoma. <i>Diagnostics</i> , 2020, 10, 410.	1.3	5
310	Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy. <i>Current Opinion in Pharmacology</i> , 2020, 54, 1-10.	1.7	35
311	Immune Checkpoint Inhibition-Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 587-603.	0.8	3
312	Evolution of Immune Checkpoint Blockade-Induced Myocarditis Over 2 Years. <i>JACC: Case Reports</i> , 2020, 2, 203-209.	0.3	5
313	Balancing Cancer Immunotherapy Efficacy and Toxicity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2898-2906.	2.0	28
314	Development and applications of computer image analysis algorithms for scoring of PD-L1 immunohistochemistry. <i>Immuno-Oncology Technology</i> , 2020, 6, 2-8.	0.2	26

#	ARTICLE	IF	CITATIONS
315	The Contribution of Epigenetics to Cancer Immunotherapy. <i>Trends in Immunology</i> , 2020, 41, 676-691.	2.9	133
316	Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations. <i>Gynecologic Oncology</i> , 2020, 158, 531-537.	0.6	8
317	Toxicities of novel therapies for hematologic malignancies. <i>Expert Review of Hematology</i> , 2020, 13, 241-257.	1.0	2
318	Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer. <i>Immunology Letters</i> , 2020, 221, 61-71.	1.1	12
319	Polymorphism of toll-like receptor genes and autoimmune endocrine diseases. <i>Autoimmunity Reviews</i> , 2020, 19, 102496.	2.5	28
320	Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. <i>OncImmunity</i> , 2020, 9, 1722023.	2.1	37
321	Checkpoint Inhibitor-Induced Colitis. <i>American Journal of Gastroenterology</i> , 2020, 115, 202-210.	0.2	68
322	Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2019, 10, 1671.	1.6	40
323	Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 5.	1.6	12
324	Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. <i>Annals of Neurology</i> , 2020, 87, 659-669.	2.8	137
326	Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies. <i>Journal of the American College of Cardiology</i> , 2020, 75, 620-628.	1.2	49
327	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. <i>European Heart Journal</i> , 2020, 41, 1733-1743.	1.0	212
328	Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis. <i>European Respiratory Journal</i> , 2020, 55, 2000038.	3.1	19
329	Resistance to Checkpoint Inhibition in Cancer Immunotherapy. <i>Translational Oncology</i> , 2020, 13, 100738.	1.7	173
330	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 307-319.	1.8	310
331	A review of cancer immunotherapy toxicity. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 86-104.	157.7	753
332	The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. <i>Cell Research</i> , 2020, 30, 285-299.	5.7	129
333	Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. <i>Annals of Surgical Oncology</i> , 2020, 27, 1533-1545.	0.7	6

#	ARTICLE	IF	CITATIONS
334	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 556.	1.8	21
335	Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report. <i>Cardiovascular Pathology</i> , 2020, 46, 107202.	0.7	25
336	Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis. <i>Cancer Investigation</i> , 2020, 38, 130-138.	0.6	14
337	Management of immune checkpoint inhibitor-related adverse events: A review of case reports. <i>Thoracic Cancer</i> , 2020, 11, 498-504.	0.8	10
338	Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. <i>Journal of the American Heart Association</i> , 2020, 9, e013757.	1.6	240
339	Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 137-145.	1.1	16
340	Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1393-1403.e1.	2.4	47
341	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 176-183.	5.7	201
342	Aberrant sialylation in ovarian cancers. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 337-344.	0.6	42
344	Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1473-1483.	1.8	23
345	Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. <i>European Journal of Cancer</i> , 2020, 131, 18-26.	1.3	50
346	Advances in living cell-based anticancer therapeutics. <i>Biomaterials Science</i> , 2020, 8, 2344-2365.	2.6	22
347	Autoimmune complications of immunotherapy: pathophysiology and management. <i>BMJ, The</i> , 2020, 369, m736.	3.0	79
348	Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy. <i>Diagnostics</i> , 2020, 10, 216.	1.3	13
349	Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors. <i>Liver International</i> , 2020, 40, 1906-1916.	1.9	43
350	Peri-tumor administration of controlled release anti-CTLA-4 synergizes with systemic anti-PD-1 to induce systemic antitumor immunity while sparing autoimmune toxicity. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1737-1749.	2.0	6
351	Diffuse large B-cell lymphoma after nivolumab treatment for lung cancer: A case report and a World Health Organization pharmacovigilance database review. <i>European Journal of Cancer</i> , 2020, 130, 20-22.	1.3	1
353	Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. <i>JAMA Oncology</i> , 2020, 6, 865.	3.4	295

#	ARTICLE	IF	CITATIONS
355	Immunologic adverse events from immune checkpoint therapy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101511.	1.4	3
356	Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database. <i>Journal of Autoimmunity</i> , 2020, 111, 102454.	3.0	11
357	A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. <i>Medicine (United States)</i> , 2020, 99, e19741.	0.4	19
358	Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry. <i>Clinical Cancer Research</i> , 2020, 26, 2268-2274.	3.2	112
359	SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 883-894.	1.6	48
360	Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. <i>BMC Medicine</i> , 2020, 18, 87.	2.3	189
361	A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China. <i>Chinese Clinical Oncology</i> , 2020, 9, 16-16.	0.4	23
362	Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology. <i>PLoS Pathogens</i> , 2020, 16, e1008340.	2.1	11
363	Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 258.	1.3	35
364	Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort. <i>Visceral Medicine</i> , 2021, 37, 87-93.	0.5	6
365	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.5	153
366	Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 527-541.	1.1	5
367	Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE). <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e109-e116.	0.7	6
368	Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors. <i>Archives of Dermatological Research</i> , 2021, 313, 1-10.	1.1	14
369	Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study. <i>Clinical and Translational Oncology</i> , 2021, 23, 389-396.	1.2	17
370	Advances on immune-related adverse events associated with immune checkpoint inhibitors. <i>Frontiers of Medicine</i> , 2021, 15, 33-42.	1.5	24
371	Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 739-746.	0.5	18
372	New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 716-721.	0.5	12

#	ARTICLE	IF	CITATIONS
373	Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 113-134.	4.2	40
374	Hepatitis B reactivation and immune check point inhibitors. <i>Digestive and Liver Disease</i> , 2021, 53, 452-455.	0.4	15
375	Improving safety of cancer immunotherapy via delivery technology. <i>Biomaterials</i> , 2021, 265, 120407.	5.7	22
376	Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. <i>Modern Pathology</i> , 2021, 34, 823-833.	2.9	6
377	AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. <i>Gastroenterology</i> , 2021, 160, 1384-1393.	0.6	121
378	PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. <i>Journal of Advanced Research</i> , 2021, 29, 45-54.	4.4	31
379	Is Viral Vector Gene Delivery More Effective Using Biomaterials?. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001238.	3.9	34
380	Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1527-1540.	2.0	21
381	Case series review of neuroradiologic changes associated with immune checkpoint inhibitor therapy. <i>Neuro-Oncology Practice</i> , 2021, 8, 247-258.	1.0	3
382	Adverse events reporting in phase 3 oncology clinical trials of checkpoint inhibitors: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103162.	2.0	1
383	Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage. <i>Journal of Chemotherapy</i> , 2021, 33, 32-39.	0.7	9
384	Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies. <i>Critical Care Clinics</i> , 2021, 37, 47-67.	1.0	5
385	Frontiers in cancer immunotherapy—a symposium report. <i>Annals of the New York Academy of Sciences</i> , 2021, 1489, 30-47.	1.8	39
386	Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. <i>Cancer Medicine</i> , 2021, 10, 188-198.	1.3	11
387	Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Thoracic Cancer</i> , 2021, 12, 153-164.	0.8	28
388	Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies. <i>Journal of Thoracic Oncology</i> , 2021, 16, 381-394.	0.5	12
389	The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. <i>European Heart Journal</i> , 2021, 42, 1621-1631.	1.0	102
390	Cardiotoxicity Related to Immune Checkpoint Inhibitors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.4	1

#	ARTICLE	IF	CITATIONS
391	Promising novel therapies for relapsed and refractory testicular germ cell tumors. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 53-69.	1.1	4
392	Cost-effectiveness of nivolumab in advanced melanoma: a drug review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 13-28.	0.7	1
393	Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis. <i>EBioMedicine</i> , 2021, 63, 103137.	2.7	44
394	Inhaled cytotoxic chemotherapy: clinical challenges, recent developments, and future prospects. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 333-354.	2.4	17
395	Oncologic Emergencies. <i>Critical Care Clinics</i> , 2021, 37, 85-103.	1.0	13
396	Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 85-112.	4.2	50
397	Emerging cancer therapies and cardiovascular risk. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 837-845.	1.0	0
398	Influenza vaccine combined with moderate-dose PD1 blockade reduces amyloid- β^2 accumulation and improves cognition in APP/PS1 mice. <i>Brain, Behavior, and Immunity</i> , 2021, 91, 128-141.	2.0	16
399	T α cell responses and therapies against SARS-CoV-2 infection. <i>Immunology</i> , 2021, 162, 30-43.	2.0	159
400	Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade. <i>Acta Clinica Belgica</i> , 2021, 76, 144-148.	0.5	2
401	Brain Stem Encephalitis in a Patient With Recurrent Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor: Case Presentation and Review of the Literature. <i>Cureus</i> , 2021, 13, e13034.	0.2	8
402	Immunotherapy-related toxicity in lung cancer: clinical characteristics and managing strategy. <i>Chinese Medical Journal</i> , 2021, 134, 780-782.	0.9	1
403	PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100379.	0.7	2
404	Fatal Immune Checkpoint Inhibitor-related Pancreatitis. <i>Internal Medicine</i> , 2021, 60, 3905-3911.	0.3	15
405	Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2385-2388.	2.0	3
406	Review of immune checkpoint inhibitors in immuno-oncology. <i>Advances in Pharmacology</i> , 2021, 91, 111-139.	1.2	43
407	Management of Immunotherapy Adverse Events in Oncological Patients: Anti-CTLA-4, Anti-PD-1/PD-L1. <i>Reviews on Recent Clinical Trials</i> , 2021, 15, 339-346.	0.4	5
408	Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. <i>British Journal of Surgery</i> , 2021, 108, 1417-1425.	0.1	57

#	ARTICLE	IF	CITATIONS
409	GI Toxicities from Cancer Therapy. , 2021, , 341-379.		0
411	Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. , 2021, 9, e001731.		45
412	Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 2209-2221.	2.0	32
413	Fatal immune-related hepatitis with intrahepatic cholestasis and pneumonia associated with camrelizumab: A case report and literature review. Open Medicine (Poland), 2021, 16, 553-557.	0.6	5
414	Colitis inducida por inmunoterapia: ¿puede ser una colitis ulcerosa?. Gastroenterología Y Hepatología, 2021, 44, 28-29.	0.2	1
415	Infections, Immunodeficiency, and Complications of Immunomodulatory Therapies in Neuroimmunology. , 2021, , 405-415.		0
416	Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management. Urology Case Reports, 2021, 34, 101508.	0.1	19
417	Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature. Annals of Palliative Medicine, 2021, 10, 793-802.	0.5	12
418	Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems. BMC Cancer, 2021, 21, 38.	1.1	17
419	Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. Journal of Neuro-Oncology, 2021, 152, 135-144.	1.4	45
420	Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy. Current Cardiology Reports, 2021, 23, 16.	1.3	12
421	Infection: Myocarditis. , 2021, , 191-232.		0
422	Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events. JMA Journal, 2021, 4, 91-98.	0.6	13
423	Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Immunotherapy Advances, 2021, 1, ltab014.	1.2	10
424	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. Current Oncology Reports, 2021, 23, 13.	1.8	38
425	Immunotherapy-induced colitis: Could it be ulcerative colitis?. Gastroenterología Y Hepatología (English Edition), 2021, 44, 28-29.	0.0	1
426	Comorbidity and frailty assessment in renal cell carcinoma patients. World Journal of Urology, 2021, 39, 2831-2841.	1.2	7
427	Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events. Cancer Immunology, Immunotherapy, 2021, 70, 2761-2769.	2.0	7

#	ARTICLE	IF	CITATIONS
428	Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 583-590.	1.1	4
429	First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis. <i>BMJ Case Reports</i> , 2021, 14, e238851.	0.2	15
430	Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS. <i>Frontiers in Pharmacology</i> , 2021, 12, 616505.	1.6	23
431	Early Detection of Checkpoint Inhibitor-Associated Myocarditis Using 68Ga-FAPI PET/CT. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 614997.	1.1	55
432	Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021, 16, 183-186.	0.5	4
433	Gastrointestinal toxicities associated with immune checkpoint inhibitors: a disproportionality analysis leveraging VigiBase, the WHO Adverse Drug Reaction Database. <i>Journal of Zhejiang University: Science B</i> , 2021, 22, 156-164.	1.3	6
434	Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 627089.	1.2	9
435	Reações Adversas Imunomediadas em pacientes tratados com Inibidores de Checkpoints Imunológicos em um Hospital filantrópico de Salvador. <i>Research, Society and Development</i> , 2021, 10, e58510212928.	0.0	0
436	Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis. , 2021, 9, e002252.		1
437	Applying artificial intelligence for cancer immunotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3393-3405.	5.7	33
438	Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. , 2021, 9, e001884.		27
439	Perspectives on Oncolytic Salmonella in Cancer Immunotherapy—A Promising Strategy. <i>Frontiers in Immunology</i> , 2021, 12, 615930.	2.2	12
440	Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2559-2576.	2.0	40
441	Neuro-ophthalmic Complications of Immune-Checkpoint Inhibitors. <i>Seminars in Ophthalmology</i> , 2021, 36, 241-249.	0.8	6
442	Imaging of Oncologic Treatment-Related Pneumonitis: A Focused Review on Emerging Issues of Immune-Checkpoint Inhibitor Pneumonitis, From the AJR Special Series on Inflammation. <i>American Journal of Roentgenology</i> , 2021, , 1-9.	1.0	7
443	Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 564.	1.7	46
444	Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review. <i>Frontiers in Oncology</i> , 2020, 10, 585311.	1.3	69
445	Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. , 2021, 9, e001935.		38

#	ARTICLE	IF	CITATIONS
446	Understanding and treating the inflammatory adverse events of cancer immunotherapy. <i>Cell</i> , 2021, 184, 1575-1588.	13.5	111
447	Checkpoint blockade toxicities: Insights into autoimmunity and treatment. <i>Seminars in Immunology</i> , 2021, 52, 101473.	2.7	11
448	Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 1469-1488.	0.8	7
449	A case series on the safety of immunotherapy with reduced blood testing frequency in lung cancer patients. <i>International Journal of Clinical Oncology</i> , 2021, 26, 851-857.	1.0	0
450	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. <i>Oncologist</i> , 2021, 26, 514-522.	1.9	18
451	TNF in the era of immune checkpoint inhibitors: friend or foe?. <i>Nature Reviews Rheumatology</i> , 2021, 17, 213-223.	3.5	77
452	Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. <i>Radiology</i> , 2021, 298, 550-566.	3.6	53
453	Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 705-713.	1.1	4
454	The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity. <i>JACC: CardioOncology</i> , 2021, 3, 35-47.	1.7	80
455	Endokrynologiczne powikłania nowych terapii przeciwnowotworowych. <i>Postepy Higieny I Medycyny Doswiadczałnej</i> , 2021, 75, 191-198.	0.1	0
456	Long-Term Survivors of Breast Cancer: A Growing Population. , 0, , .		0
457	A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review). <i>Molecular Medicine Reports</i> , 2021, 23, .	1.1	16
458	Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China. <i>Frontiers in Oncology</i> , 2021, 11, 607531.	1.3	18
459	Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1396-1404.	3.0	56
460	Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	84
461	Rheumatic Complications of Immune Checkpoint Inhibitors. <i>Medical Clinics of North America</i> , 2021, 105, 227-245.	1.1	3
462	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
463	Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy. <i>ENeurologicalSci</i> , 2021, 22, 100324.	0.5	9

#	ARTICLE	IF	CITATIONS
464	CMR Parametric Mapping in Immune Checkpoint Inhibitor Myocarditis. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1517-1519.	1.2	3
465	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors. <i>Chest</i> , 2021, 159, 1107-1125.	0.4	53
466	Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Clinical Science</i> , 2021, 135, 703-724.	1.8	18
467	Safety of current immune checkpoint inhibitors in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 651-667.	1.0	4
468	Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin α 4 therapy. <i>European Journal of Cancer</i> , 2021, 145, 230-233.	1.3	6
469	Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents. <i>Anti-Cancer Drugs</i> , 2021, 32, 567-574.	0.7	3
470	Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. <i>Annals of Oncology</i> , 2021, 32, 375-383.	0.6	25
471	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?â€”a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1541-1552.	0.6	6
472	Immune Checkpoint Inhibitors in the Treatment of Cancer. <i>Current Clinical Pharmacology</i> , 2022, 17, 103-113.	0.2	18
473	Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1503-1516.	1.2	97
474	Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 642110.	1.3	32
475	Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. <i>Scientific Reports</i> , 2021, 11, 9029.	1.6	39
476	Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis. <i>Clinical and Translational Oncology</i> , 2021, 23, 1885-1904.	1.2	11
477	Cardiac adverse events associated with anti-PD-1 therapy in patients treated for advanced melanoma: relevance of dosing troponin T levels. <i>European Journal of Dermatology</i> , 2021, 31, 205-212.	0.3	3
478	The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases. <i>Immunotherapy</i> , 2021, 13, 527-539.	1.0	12
479	Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis. <i>Frontiers in Oncology</i> , 2021, 11, 633032.	1.3	53
480	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-10.	1.0	8
481	Immune Checkpoint Inhibitor-Related Adrenal Insufficiency. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151131.	0.7	2

#	ARTICLE	IF	CITATIONS
483	Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: two case reports. <i>Yeungnam University Journal of Medicine</i> , 2022, 39, 62-66.	0.7	3
484	Radiological assessment of response and adverse events associated with novel systemic oncological therapies. <i>Clinical Radiology</i> , 2021, 76, 247-261.	0.5	0
485	Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review. <i>Cancers</i> , 2021, 13, 1794.	1.7	38
486	Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab. <i>Medicine (United States)</i> , 2021, 100, e25402.	0.4	2
487	Endocrine toxicities of immune checkpoint inhibitors. <i>Nature Reviews Endocrinology</i> , 2021, 17, 389-399.	4.3	162
488	Adverse events induced by immune checkpoint inhibitors. <i>Current Opinion in Immunology</i> , 2021, 69, 29-38.	2.4	25
489	Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 650292.	1.3	22
490	Inflammatory markers in autoimmunity induced by checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1623-1630.	1.2	24
491	Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol. <i>The Cochrane Library</i> , 0, , .	1.5	0
492	Progressive Pulmonary Infiltrates in a Man with Mediastinal Lymphoma. <i>Annals of the American Thoracic Society</i> , 2021, 18, 884-888.	1.5	1
493	Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Current Oncology Reports</i> , 2021, 23, 79.	1.8	85
494	Role of cardiovascular magnetic resonance in early detection and treatment of cardiac dysfunction in oncology patients. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 3003-3017.	0.7	4
495	Polarization of Tumor-Associated Macrophages by Nanoparticle-Loaded <i>Escherichia coli</i> Combined with Immunogenic Cell Death for Cancer Immunotherapy. <i>Nano Letters</i> , 2021, 21, 4231-4240.	4.5	149
496	Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. <i>JAMA Oncology</i> , 2021, 7, 744.	3.4	110
497	Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 661737.	2.2	29
498	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 621639.	1.3	12
499	Neurological complications of immune checkpoint inhibitor cancer immunotherapy. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117424.	0.3	14
500	Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 641-648.	2.0	46

#	ARTICLE	IF	CITATIONS
501	Clinical Insights Into Novel Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2021, 12, 681320.	1.6	76
503	An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors. <i>Biomolecules</i> , 2021, 11, 785.	1.8	9
504	High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment. <i>European Journal of Cancer</i> , 2021, 149, 105-113.	1.3	4
506	What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. <i>Current Treatment Options in Oncology</i> , 2021, 22, 53.	1.3	2
507	Heart Failure With Targeted Cancer Therapies. <i>Circulation Research</i> , 2021, 128, 1576-1593.	2.0	33
508	The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis. <i>Immunopharmacology and Immunotoxicology</i> , 2021, 43, 386-394.	1.1	6
509	Delayed thrombocytopenia as a rare but serious adverse event secondary to immune checkpoint inhibitor: a case report. <i>Annals of Palliative Medicine</i> , 2021, 10, 33-33.	0.5	9
510	Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic. <i>Nature Communications</i> , 2021, 12, 2637.	5.8	25
511	Age-Associated Changes in Adverse Events Arising From Anti-PD-(L)1 Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 619385.	1.3	12
512	Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e483-e487.	0.2	1
513	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. <i>Circulation Research</i> , 2021, 128, 1780-1801.	2.0	48
514	Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5801.	1.8	182
515	Experiences of cancer immunotherapy with immune checkpoint inhibitors (ExCI) – insights of people affected by cancer and healthcare professionals: a qualitative study protocol. <i>BMJ Open</i> , 2021, 11, e043750.	0.8	3
516	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2653.	1.7	2
517	Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer. <i>Cancers</i> , 2021, 13, 2316.	1.7	5
518	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 76-91.	1.3	33
519	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1623-1634.	1.4	10
520	Clinical and Hematological Predictors of High-Grade Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors. <i>Journal of Clinical Medicine Research</i> , 2021, 13, 268-275.	0.6	7

#	ARTICLE	IF	CITATIONS
521	Role of Cardiac Imaging in the Diagnosis of Immune Checkpoints Inhibitors Related Myocarditis. <i>Frontiers in Oncology</i> , 2021, 11, 640985.	1.3	9
522	A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors. <i>Cardio-Oncology</i> , 2021, 7, 19.	0.8	14
523	Guillain-Barre Syndrome in a patient with uterine adenocarcinoma undergoing treatment with immune-checkpoint inhibitor therapy: A case report and review of the literature. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100739.	0.3	7
524	Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity. <i>British Journal of Dermatology</i> , 2021, 185, 627-635.	1.4	12
525	Integration of Salmonella into Combination Cancer Therapy. <i>Cancers</i> , 2021, 13, 3228.	1.7	15
526	Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem. , 2021, 9, e002916.		29
527	Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients. , 2021, 9, e002512.		8
528	Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis. <i>European Radiology</i> , 2021, 31, 8868-8878.	2.3	2
529	Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer. <i>Journal of Investigative Medicine</i> , 2021, 69, 1281-1286.	0.7	0
530	Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6246.	1.8	8
531	Immune-related cutaneous adverse events due to checkpoint inhibitors. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 613-622.	0.5	12
532	Managing side effects of immune checkpoint inhibitors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103354.	2.0	15
533	Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3069-3080.	2.0	31
534	Monitoring Immunotherapy With Optical Molecular Imaging. <i>ChemMedChem</i> , 2021, 16, 2547-2557.	1.6	6
535	The dark side of immunotherapy. <i>Annals of Translational Medicine</i> , 2021, 9, 1041-1041.	0.7	12
536	Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Decade of Progress. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e105-e127.	1.8	67
537	Why are immune adverse events so common with checkpoint inhibitor therapy?. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 608-610.	0.5	4
538	Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe. <i>Insights Into Imaging</i> , 2021, 12, 76.	1.6	35

#	ARTICLE	IF	CITATIONS
539	Spatially Localized Immunotherapy: A Perfect Combination With Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2021, 110, 507-509.	0.4	1
540	The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review. Translational Lung Cancer Research, 2021, 10, 2752-2765.	1.3	5
541	Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 703893.	1.3	33
542	Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies. BMC Medical Informatics and Decision Making, 2021, 21, 205.	1.5	15
543	Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance. Drug Safety, 2021, 44, 957-971.	1.4	38
544	Efficacy of artificial liver support system in severe immune-associated hepatitis caused by camrelizumab: A case report and review of the literature. World Journal of Clinical Cases, 2021, 9, 4415-4422.	0.3	7
545	Chimeric antigen receptor ^T-cells safety: A pharmacovigilance and meta-analysis study. American Journal of Hematology, 2021, 96, 1101-1111.	2.0	14
546	Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer. Thoracic Cancer, 2021, 12, 2198-2204.	0.8	19
547	Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. Cancers, 2021, 13, 2931.	1.7	19
548	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
549	Immune checkpoint inhibitors: current status. BMJ Supportive and Palliative Care, 2021, , bmjspcare-2021-002954.	0.8	1
550	Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review. Translational Lung Cancer Research, 2021, 10, 3014-3028.	1.3	9
551	Immune checkpoint inhibitors in lymphoma: challenges and opportunities. Annals of Translational Medicine, 2021, 9, 1037-1037.	0.7	30
552	Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. International Immunopharmacology, 2021, 95, 107498.	1.7	45
553	Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review. Cardio-Oncology, 2021, 7, 26.	0.8	3
554	Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. Cancers, 2021, 13, 3415.	1.7	15
555	Clinical Research on the Mechanisms Underlying Immune Checkpoints and Tumor Metastasis. Frontiers in Oncology, 2021, 11, 693321.	1.3	16
556	CX-072 (pacmilimab), a Probody[®]-PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. , 2021, 9, e002447.		26

#	ARTICLE	IF	CITATIONS
557	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
558	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 495-508.	21.5	120
559	Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis. , 2021, 9, e002732.		12
560	Progressive multifocal leukoencephalopathy in systemic lupus erythematosus managed with pembrolizumab: A case report with literature review. <i>Lupus</i> , 2021, 30, 1849-1855.	0.8	5
561	Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis. <i>JAMA Cardiology</i> , 2021, 6, 1329.	3.0	64
562	Immunotherapy in Older Adults With Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2115-2127.	0.8	33
563	The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 436.e1-436.e8.	0.8	6
564	Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3077-3088.	1.6	5
565	Hypersensitivity and Immune-related Adverse Events in Biologic Therapy. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 413-431.	2.9	6
566	Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review. <i>Frontiers in Immunology</i> , 2021, 12, 682262.	2.2	13
567	CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. , 2021, 9, e002446.		16
568	Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Current Cardiology Reports</i> , 2021, 23, 98.	1.3	34
569	Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States. <i>JCO Oncology Practice</i> , 2021, , OP.21.00140.	1.4	6
570	Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2021, 15, 336.	0.4	7
571	Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 679095.	1.3	7
572	Hemophagocytic lymphohistiocytosis due to pembrolizumab therapy for adenocarcinoma of the lung. <i>Baylor University Medical Center Proceedings</i> , 2021, 34, 1-2.	0.2	0
573	Laryngeal Cancer With Lung Metastases Showing Long-Term Complete Response and Delayed Immune-Related Adverse Event After Nivolumab Discontinuation. <i>Ear, Nose and Throat Journal</i> , 2021, , 014556132110310.	0.4	2
574	Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure. <i>Melanoma Research</i> , 2021, 31, 464-471.	0.6	2

#	ARTICLE	IF	CITATIONS
575	Serum Troponin T Concentrations Are Frequently Elevated in Advanced Skin Cancer Patients Prior to Immune Checkpoint Inhibitor Therapy: Experience From a Single Tertiary Referral Center. <i>Frontiers in Medicine</i> , 2021, 8, 691618.	1.2	4
576	Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2021, 96, 107796.	1.7	12
577	Long-term response to immuno-oncology after discontinuation for immuno-related pneumonia in metastatic renal carcinoma. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	1
578	Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	4
579	Non-neoplastic inflammatory pseudotumor of the lung after immunotherapy for melanoma: A diagnostic pitfall on fine needle aspiration biopsy of lung. <i>Diagnostic Cytopathology</i> , 2021, 49, 1150-1154.	0.5	1
580	Toxicity of Immunotherapeutic Agents. <i>Critical Care Clinics</i> , 2021, 37, 605-624.	1.0	2
581	Reinforcing the Combinational Immuno-Oncotherapy of Switching "Cold" Tumor to "Hot" by Responsive Penetrating Nanogels. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 36824-36838.	4.0	24
582	Non-invasive Detection of Immunotherapy-Induced Adverse Events. <i>Clinical Cancer Research</i> , 2021, 27, 5353-5364.	3.2	13
583	Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. <i>European Journal of Cancer</i> , 2021, 153, 168-178.	1.3	14
584	Deciphering the Dynamic Complexities of the Liver Microenvironment " Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI). <i>AAPS Journal</i> , 2021, 23, 99.	2.2	1
585	The Need for Critical Examination of Disparities in Immunotherapy and Targeted Therapy Use Among Patients With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1115.	3.4	2
586	A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab342.	0.3	23
587	Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 ⁺ T cells and an infiltration pattern that resembles ulcerative colitis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 1119-1129.	1.4	11
588	Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. <i>Scientific Reports</i> , 2021, 11, 17324.	1.6	24
589	Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 701951.	2.2	25
590	Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome. <i>American Journal of Emergency Medicine</i> , 2021, 46, 51-55.	0.7	26
591	Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2021, 13, 1271-1282.	1.0	13
592	Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. <i>Biomedicines</i> , 2021, 9, 1075.	1.4	46

#	ARTICLE	IF	CITATIONS
593	Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab. <i>Clinical Lung Cancer</i> , 2022, 23, 34-42.	1.1	18
594	Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators. <i>Journal of Translational Medicine</i> , 2021, 19, 328.	1.8	4
595	Pembrolizumab-induced autoimmune Stevens-Johnson syndrome/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: a case report. <i>Translational Cancer Research</i> , 2021, 10, 3870-3876.	0.4	13
596	Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma. <i>Immunotherapy</i> , 2021, 13, 1011-1029.	1.0	8
597	Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer. <i>Chest</i> , 2021, 160, 731-742.	0.4	64
598	Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events—Reply. <i>JAMA Oncology</i> , 2021, 7, 1574-1575.	3.4	2
599	ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO). <i>European Heart Journal Supplements</i> , 2021, 23, C128-C153.	0.0	7
601	Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e498-e505.	0.5	32
602	Immune checkpoint inhibitor-related hepatotoxicity: A review. <i>World Journal of Gastroenterology</i> , 2021, 27, 5376-5391.	1.4	52
603	Case Report: The Neuromuscular Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 714460.	1.1	12
604	The Role of Neoantigens in Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 682325.	1.3	14
605	Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. , 2021, 9, e002804.		5
606	The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. <i>Cancer Epidemiology</i> , 2021, 73, 101943.	0.8	21
607	Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 708195.	1.3	16
608	<sc>PD</sc>-1</sc> blockade: Prospectives for immunotherapy in cancer and autoimmunity. <i>IUBMB Life</i> , 2021, 73, 1293-1306.	1.5	11
609	Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy. <i>Immunological Medicine</i> , 2022, 45, 108-118.	1.4	10
610	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		9
611	Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database. <i>International Immunopharmacology</i> , 2021, 98, 107818.	1.7	12

#	ARTICLE	IF	CITATIONS
612	Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study. , 2021, 9, e002960.		16
613	A case report of advanced thymoma re-treated with PD-1 inhibitor after initial immune-related pneumonitis. Annals of Palliative Medicine, 2021, 10, 10083-10090.	0.5	2
614	Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases. Cancers, 2021, 13, 4928.	1.7	10
615	Immune PET Imaging. Radiologic Clinics of North America, 2021, 59, 875-886.	0.9	2
616	Patient colon and rectal operative outcomes when treated with immune checkpoint inhibitors. European Journal of Surgical Oncology, 2021, 47, 2436-2440.	0.5	2
617	Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors. Digestion, 2021, 102, 965-973.	1.2	2
618	Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis. Cancer Investigation, 2021, 39, 789-796.	0.6	5
619	Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies. International Journal of Cardiology, 2021, 344, 170-178.	0.8	13
620	Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. Cancers, 2021, 13, 4797.	1.7	12
621	Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncology, The, 2021, 22, 1265-1274.	5.1	102
622	The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events. Frontiers in Oncology, 2021, 11, 704475.	1.3	7
623	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
624	Novel Therapies in Oncology: An Individualized Approach. AACN Advanced Critical Care, 2021, 32, 315-323.	0.6	1
625	A Case of Lung Adenocarcinoma with Pulmonary Hypertrophic Osteoarthropathy Showing Pathological Complete Response to a Pembrolizumab-Containing Chemoimmunotherapy. Case Reports in Oncology, 2021, 14, 1380-1386.	0.3	1
626	A Wake-Up Call for Immune Checkpoint Inhibitor-Related Pneumonitis. Journal of Thoracic Oncology, 2021, 16, 1440-1442.	0.5	0
627	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 3713-3736.	1.3	12
628	Response to letter entitled: Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. European Journal of Cancer, 2021, 155, 303-306.	1.3	2
629	The promise and perils of immunotherapy. Blood Advances, 2021, 5, 3709-3725.	2.5	23

#	ARTICLE	IF	CITATIONS
630	Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence. <i>International Immunopharmacology</i> , 2021, 98, 107876.	1.7	15
631	Immune checkpoint inhibitors in melanoma. <i>Lancet, The</i> , 2021, 398, 1002-1014.	6.3	462
632	Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 155, 299-302.	1.3	3
633	Immune-related adverse events in cancer patients being treated with immune checkpoint inhibitors. <i>European Journal of Haematology</i> , 2021, 107, 650-657.	1.1	4
634	Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103434.	2.0	26
635	Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types. <i>Npj Precision Oncology</i> , 2021, 5, 82.	2.3	14
636	Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, 3-8.	0.5	9
637	Efficacy and safety profile of avelumab monotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103464.	2.0	2
638	Dynamic Changes of Serum Heart Type-Fatty Acid Binding Protein in Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2021, 12, 748677.	1.6	8
639	Immune Checkpoint Inhibitor Colitis: Resident Memory Unleashed. <i>Gastroenterology</i> , 2021, 161, 1106-1108.	0.6	3
640	Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100220.	0.6	4
641	Interferon-Gamma ⁺ -Producing CD8 ⁺ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor ⁺ Colitis. <i>Gastroenterology</i> , 2021, 161, 1229-1244.e9.	0.6	87
642	Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. <i>Brain Communications</i> , 2021, 3, fcab220.	1.5	16
643	Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody. <i>Cancer Letters</i> , 2021, 518, 49-58.	3.2	17
644	Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. <i>European Journal of Cancer</i> , 2021, 157, 383-390.	1.3	6
645	Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity. <i>European Journal of Cancer</i> , 2021, 157, 10-20.	1.3	4
646	Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. <i>Cancer Treatment Reviews</i> , 2021, 100, 102282.	3.4	25
647	Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 160, 121-127.	0.9	6

#	ARTICLE	IF	CITATIONS
648	Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102280.	3.4	10
649	Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. <i>European Journal of Cancer</i> , 2021, 157, 214-224.	1.3	62
650	Ocular side effects of checkpoint inhibitors. <i>Survey of Ophthalmology</i> , 2021, 66, 951-959.	1.7	16
651	Acute development of fatal myocarditis after pembrolizumab in non-small-cell lung cancer with thymoma. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100105.	0.1	0
652	Preclinical and clinical toxicity of immuno-oncology therapies and mitigation strategies. , 2022, , 499-513.		0
653	Proteomic biomarker technology for cancer immunotherapy. , 2022, , 357-397.		0
654	Oral Immune-Related Adverse Events “ Current Concepts and their Management. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 604-609.	0.7	2
655	Efficacy and Safety of Vedolizumab and Infliximab Treatment for Immune-Mediated Diarrhea and Colitis in Cancer Patients: A Multi-Center Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
656	Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. <i>Scientific Reports</i> , 2021, 11, 1324.	1.6	38
657	New Onset Ocular Myasthenia Gravis After Pembrolizumab Therapy: a Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 309-311.	0.3	3
658	Immune Checkpoint Inhibitor (ICI)-Associated Myocarditis. , 2021, , 27-37.		0
659	Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors. <i>Current Cancer Research</i> , 2021, , 139-173.	0.2	0
660	Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor Immunity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
662	Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232097699.	1.1	12
663	A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. <i>OncImmunology</i> , 2021, 10, 1875639.	2.1	30
664	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	1.0	213
665	OUP accepted manuscript. <i>European Heart Journal</i> , 2021, , .	1.0	7
666	Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 277-285.	0.8	9

#	ARTICLE	IF	CITATIONS
667	SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 213-222.	1.2	14
668	The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. <i>BioDrugs</i> , 2020, 34, 495-503.	2.2	15
670	Immune Checkpoint Inhibitor Myocarditis With Normal Cardiac Magnetic Resonance Imaging: Importance of Cardiac Biopsy and Early Diagnosis. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1654-1656.	0.8	5
671	Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity. <i>International Immunopharmacology</i> , 2020, 84, 106584.	1.7	13
672	Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. <i>International Immunopharmacology</i> , 2020, 84, 106601.	1.7	35
673	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. <i>Medicina Clínica</i> , 2020, 155, 541-547.	0.3	8
674	Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer. <i>Bioscience Reports</i> , 2020, 40, .	1.1	29
675	Challenges of Cancer Immunotherapy during the COVID-19 Pandemic. <i>Cancer Investigation</i> , 2021, 39, 1-5.	0.6	7
676	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1047-1059.	1.4	9
677	Durvalumab for the treatment of PD-L1 non-small cell lung cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 95-105.	0.4	1
678	Practical cardiovascular imaging approach to diagnose immune checkpoint inhibitor myocarditis. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 372-374.	0.5	6
679	Time to dissect the autoimmune etiology of cancer antibody immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 51-61.	3.9	66
680	Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit. <i>Annals of Intensive Care</i> , 2020, 10, 143.	2.2	24
681	Lambert-Eaton Myasthenic Syndrome, Botulism, and Immune Checkpoint Inhibitor-Related Myasthenia Gravis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 1785-1806.	0.4	12
682	Anticancer Drugs and the Nervous System. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 732-764.	0.4	13
683	Cardio-oncology for the general physician: old and new cardiovascular toxicities and how to manage them. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2020, 81, 1-11.	0.2	2
684	Gastrointestinal toxicities of immune checkpoint inhibitors: a multicenter retrospective analysis. <i>Annals of Gastroenterology</i> , 2020, 34, 46-52.	0.4	2
685	The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. <i>Cancer Biology and Medicine</i> , 2020, 17, 599-611.	1.4	45

#	ARTICLE	IF	CITATIONS
686	Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review. <i>Current Medicinal Chemistry</i> , 2020, 27, 4673-4698.	1.2	18
687	Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study. <i>JMIR Formative Research</i> , 2020, 4, e17898.	0.7	17
688	Predicting Onset and Continuity of Patient-Reported Symptoms in Patients Receiving Immune Checkpoint Inhibitor (ICI) Therapies Using Machine Learning. <i>Archives of Clinical and Medical Case Reports</i> , 2020, 04, .	0.0	3
689	Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. <i>Frontiers in Endocrinology</i> , 2020, 11, 576027.	1.5	20
690	Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 339.	2.2	77
691	Cardiovascular Complications of Prostate Cancer Treatment. <i>Frontiers in Pharmacology</i> , 2020, 11, 555475.	1.6	14
692	Monoclonal Antibody-Based Immunotherapy and Its Role in the Development of Cardiac Toxicity. <i>Cancers</i> , 2021, 13, 86.	1.7	14
693	Diretriz Brasileira de Cardio-oncologia " 2020. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 115, 1006-1043.	0.3	37
694	Adverse effects of immuno-oncology drugs" Awareness, diagnosis, and management: A literature review of immune-mediated adverse events. <i>Indian Journal of Cancer</i> , 2019, 56, 10.	0.2	3
695	Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy. <i>Immune Network</i> , 2020, 20, e8.	1.6	19
696	Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2019, 10, 17-28.	0.5	26
697	Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 255-289.	2.3	393
698	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 367-402.	2.3	326
699	Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 750-757.	2.3	86
700	NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 230-241.	2.3	284
701	Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1191-1199.	2.3	27
702	Immune Checkpoint Inhibitor-induced Fanconi Syndrome. <i>Cureus</i> , 2020, 12, e7686.	0.2	9
703	An Unusual Presentation of Inflammatory Shoulder Arthritis Associated with Nivolumab. <i>JBJS Case Connector</i> , 2021, 11, .	0.1	1

#	ARTICLE	IF	CITATIONS
704	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 686876.	1.6	9
705	Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma. <i>British Journal of Ophthalmology</i> , 2023, 107, 320-323.	2.1	8
706	Antigen presentation by lung epithelial cells directs CD4+ TRM cell function and regulates barrier immunity. <i>Nature Communications</i> , 2021, 12, 5834.	5.8	58
707	CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma. <i>Nano Research</i> , 2022, 15, 2300-2314.	5.8	12
708	Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 743582.	1.6	14
709	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. <i>Cell</i> , 2021, 184, 5309-5337.	13.5	588
710	Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5134.	1.7	8
711	Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 508.	0.4	10
712	Thirty-day mortality rates after immunotherapy initiation. <i>Immunotherapy</i> , 2021, 13, 1419-1426.	1.0	2
713	Pulmonary adverse events due to immune checkpoint inhibitors: A literature review. <i>Monaldi Archives for Chest Disease</i> , 2021, , .	0.3	0
714	The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. <i>European Journal of Cancer</i> , 2021, 158, 217-224.	1.3	35
715	Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis. <i>Biomedicines</i> , 2021, 9, 1484.	1.4	10
716	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 765608.	1.3	10
717	Cardiac MRI in Immune Checkpoint Inhibitor Associated Pericarditis. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04926.	0.2	2
718	Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188636.	3.3	27
719	The progress of immune checkpoint therapy in primary liver cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188638.	3.3	29
720	Therapeutic supramolecular tubustecan hydrogel combined with checkpoint inhibitor elicits immunity to combat cancer. <i>Biomaterials</i> , 2021, 279, 121182.	5.7	22
722	Management of Adverse Events Induced by Immune Checkpoint Inhibitors in Lung Cancer Treatment. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 231-237.	0.0	0

#	ARTICLE	IF	CITATIONS
723	Hypophysite et hÃ©patite secondaires Ã une immunothÃ©rapie par inhibiteur des points de contrÃ©le. Annales Francaises De Medecine D'Urgence, 2019, 9, 334-337.	0.0	1
724	ToxicitÃ©s pulmonaires des immunothÃ©rapies : Ã©valuer et traiter. Revue Des Maladies Respiratoires Actualites, 2019, 11, S491-S501.	0.0	0
725	Immune-related adverse events associated with immune check-point inhibitors. Klinicka Farmakologie A Farmacie, 2019, 33, 20-24.	0.1	2
726	GI Toxicities from Cancer Therapy. , 2020, , 1-39.		0
727	Immune-related adverse events associated with cancer immunotherapy. Practical Oncology, 2019, 2, 24-44.	0.1	0
728	Onkologika. , 2020, , 671-732.		2
729	Immune-related neutropenia in cancer patients â€“ review. Oncolog-Hematolog Ro, 2020, 2, 24.	0.0	0
730	Pembrolizumab: The Nut Cracker. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 393-396.	0.1	0
731	A Case of Acute Heart Failure Following Immunotherapy for Metastatic Lung Cancer. Cureus, 2020, 12, e8093.	0.2	7
732	Immunotherapy in elderly patients: should we stay or should we go?. Future Oncology, 2020, 16, 973-974.	1.1	3
733	How to manage side effects of immunotherapy. Onkologie (Czech Republic), 2020, 14, 6-12.	0.0	0
734	Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis. Cureus, 2020, 12, e8613.	0.2	7
736	Side effects and management in immunotherapy based on immune checkpoint inhibitors. World Chinese Journal of Digestology, 2020, 28, 755-764.	0.0	1
737	A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Antiâ€“CTLA-4 and Antiâ€“PD-1 Blockade in Rare Tumors (DART, SWOG) Tj ETQqã.ã 0.7843ã4 rgBT		
738	Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis. Frontiers in Immunology, 2021, 12, 768957.	2.2	22
739	Gut microbiome and checkpoint inhibitor colitis. Intestinal Research, 2021, 19, 360-364.	1.0	14
740	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. Clinical Immunology, 2021, 232, 108873.	1.4	19
741	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 4073-4126.	0.8	580

#	ARTICLE	IF	CITATIONS
742	Diagnosis and Management of Checkpoint Inhibitor Side Effects in Patients with Bladder Cancer: the Urologist's Perspective. <i>Bladder Cancer</i> , 2020, 6, 425-433.	0.2	0
744	Molecular Pathology of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>Journal of Analytical Oncology</i> , 0, 9, 25-32.	0.1	1
747	A Case of Isolated ACTH Deficiency and Polyarthritis during Nivolumab Therapy for Gastric Cancer. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2020, 81, 1120-1126.	0.0	0
749	Immune-related adverse events from immune checkpoint inhibitors: Review of risk factors in clinical practice. <i>Pharmaceutical Sciences Asia</i> , 2020, 47, 104-112.	0.2	2
750	Pembrolizumab-Induced Diabetic Ketoacidosis: A Review of Critical Care Case. <i>Cureus</i> , 2021, 13, e18983.	0.2	3
751	Immune-Related Cerebellar Ataxia: A Rare Adverse Effect of Checkpoint Inhibitor Therapy. <i>Journal of NeuroImmune Pharmacology</i> , 2022, 17, 377-379.	2.1	7
752	Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies. <i>Frontiers in Pharmacology</i> , 2021, 12, 747416.	1.6	0
753	Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease. <i>Cancer Management and Research</i> , 2021, Volume 13, 8199-8208.	0.9	9
754	Central Nervous System Disorders Associated To Immune Checkpoint Inhibitors. <i>Current Cancer Therapy Reviews</i> , 2021, 17, .	0.2	0
755	Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 5160.	1.0	20
756	Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review. <i>Ecancermedalscience</i> , 2021, 15, 1314.	0.6	1
757	An Inter-supplementary Biohybrid System Based on Natural Killer Cells for the Combinational Immunotherapy and Virotherapy of Cancer. <i>Advanced Science</i> , 2022, 9, e2103470.	5.6	9
758	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1856.	3.4	74
759	A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy. <i>Aging</i> , 2020, 12, 18741-18753.	1.4	19
760	Imaging Spectrum of Infections in the Setting of Immunotherapy and Molecular Targeted Therapy. <i>Current Problems in Diagnostic Radiology</i> , 2022, 51, 86-97.	0.6	1
761	Role of Infliximab in Immune Checkpoint Inhibitor-Induced Pneumonitis. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 172-174.	0.6	5
762	Immunotherapy induced enterocolitis and gastritis – What to do and when?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 48-49, 101703.	1.0	8
763	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy. <i>Anesthesia and Analgesia</i> , 2021, 132, 374-383.	1.1	8

#	ARTICLE	IF	CITATIONS
770	Gastrointestinal and liver adverse effects of anti-tumoral immune therapy: from recognition to treatment. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2021, 14, 195-199.	0.6	0
771	Neoadjuvant immunotherapy for resectable non-small cell lung cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 2521-2536.	1.4	2
772	Diagnosis and Management of Immune Checkpoint Inhibitor Colitis. <i>Gastroenterology and Hepatology</i> , 2021, 17, 358-366.	0.2	3
773	Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110562.	0.6	5
774	Gastrointestinal adverse events of immunotherapy. <i>BJR Open</i> , 2021, 3, .	0.4	0
775	Immune Checkpoint Blockade and Skin Toxicity Pathogenesis. <i>Journal of Investigative Dermatology</i> , 2021, , .	0.3	11
776	Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein-Barr Virus. <i>Biomolecules</i> , 2021, 11, 1792.	1.8	4
777	Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in the Large Arteries of Lymphoma Patients under 50 Years of Age. <i>Biology</i> , 2021, 10, 1206.	1.3	3
778	A review of neurotoxicities associated with immunotherapy and a framework for evaluation. <i>Neuro-Oncology Advances</i> , 2021, 3, v108-v120.	0.4	6
779	Anticancer natural products targeting immune checkpoint protein network. <i>Seminars in Cancer Biology</i> , 2022, 86, 1008-1032.	4.3	8
780	The Use of PET in Evaluating the Efficacy of Immunotherapy in Oncology. , 2022, , 471-493.		0
781	Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 1-9.	1.1	10
782	From cardio-oncology to cardio-onco-pharmacology: Towards a multidisciplinary approach in the understanding and management of cardiotoxicity. <i>Therapie</i> , 2022, 77, 197-206.	0.6	1
783	Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. , 2021, 9, e003277.		49
784	Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 786046.	2.2	17
785	Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 751159.	1.3	16
786	Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 797852.	1.6	8
787	CheckMate-067: Raising the Bar for the Next Decade in Oncology. <i>Journal of Clinical Oncology</i> , 2022, 40, 111-113.	0.8	8

#	ARTICLE	IF	CITATIONS
788	How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors. <i>ESMO Open</i> , 2021, 6, 100317.	2.0	10
789	Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 377-387.	0.8	2
790	Colitis Induced by Immune-checkpoint Inhibitors. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2021, 74, 599-605.	0.1	0
791	Hepatobiliary and Pancreatic Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 339-355.	0.8	6
792	Pulmonary Toxicities of Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 357-375.	0.8	4
793	<i>Onkologika.</i> , 2021, , 579-638.		0
794	Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma. <i>Cancers</i> , 2022, 14, 302.	1.7	15
795	Immunotherapy toxicity: identification and management. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 1-17.	1.1	24
796	Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. <i>BMC Cancer</i> , 2022, 22, 55.	1.1	14
797	Adverse events of immunotherapy in non-small cell lung cancer: A systematic review and network meta-analysis. <i>International Immunopharmacology</i> , 2022, 102, 108353.	1.7	19
798	Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 778185.	1.3	10
799	Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer. <i>Cancers</i> , 2022, 14, 294.	1.7	24
800	Immunotherapy in older patients with hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2022, 162, 76-98.	1.3	8
801	Immune Checkpoint Inhibitor Induced Pericarditis and Encephalitis in a Patient Treated With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2021, 11, 749834.	1.3	8
802	Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment. <i>Frontiers in Pharmacology</i> , 2021, 12, 770631.	1.6	23
803	Immune-related adverse events and the balancing act of immunotherapy. <i>Nature Communications</i> , 2022, 13, 392.	5.8	125
804	Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition. , 2022, 10, e003551.		19
805	Genome editing of PD-L1 mediated by nucleobase-modified polyamidoamine for cancer immunotherapy. <i>Journal of Materials Chemistry B</i> , 2022, 10, 1291-1300.	2.9	6

#	ARTICLE	IF	CITATIONS
806	Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 616-624.	1.9	20
807	Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 802672.	2.2	2
808	Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors. <i>Neurotherapeutics</i> , 2022, 19, 848-863.	2.1	10
809	Relato de caso “ eventos neuromusculares relacionados com inibidores de checkpoint. <i>Revista Neurociencias</i> , 0, 30, 1-12.	0.0	0
810	Immune checkpoint inhibitors: immune-related adverse events, healthcare utilization, and costs among commercial and Medicare Advantage patients. <i>Supportive Care in Cancer</i> , 2022, 30, 4019-4026.	1.0	10
811	Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1455-1466.	1.5	7
812	Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 812702.	1.1	2
813	Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria. <i>European Heart Journal - Case Reports</i> , 2022, 6, ytab478.	0.3	8
814	In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-I/PD-L1 interaction. <i>Scientific Reports</i> , 2022, 12, 303.	1.6	6
815	Multiple rechallenges with anti-PD-1 immunotherapy in patients with checkpoint inhibitor-related pneumonitis: A report of two cases. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1234-1238.	0.5	1
816	Harnessing big data to characterize immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 269-280.	12.5	41
817	Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. <i>Frontiers in Immunology</i> , 2021, 12, 730666.	2.2	31
818	T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. <i>Nature Medicine</i> , 2022, 28, 353-362.	15.2	132
819	Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. , 2022, 10, e004008.		28
820	Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. , 2022, 10, e003779.		34
822	Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 81, 414-425.	0.9	40
823	Concise synthesis and biological activity evaluation of novel pyrazinyl-aryl urea derivatives against several cancer cell lines, which can especially induce T24 apoptotic and necroptotic cell death. <i>RSC Medicinal Chemistry</i> , 2022, 13, 280-299.	1.7	1
824	Risk assessment, diagnosis, and treatment of cancer treatment-related adrenal insufficiency. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 21-33.	1.2	3

#	ARTICLE	IF	CITATIONS
825	Herpes simplex encephalitis in the context of immune checkpoint inhibitors: a complex interplay. <i>Acta Neurologica Belgica</i> , 2022, 122, 823-825.	0.5	3
826	Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury. <i>Frontiers in Pharmacology</i> , 2021, 12, 786174.	1.6	8
827	Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy. <i>Nanotheranostics</i> , 2022, 6, 243-255.	2.7	17
829	Asymptomatic Myocarditis with Mild Cardiac Marker Elevation Following Nivolumab-Induced Myositis. <i>International Heart Journal</i> , 2022, 63, 180-183.	0.5	9
830	Immune-related adverse events in various organs caused by immune checkpoint inhibitors. <i>Allergology International</i> , 2022, 71, 169-178.	1.4	34
831	Immune-checkpoint inhibitors: long-term implications of toxicity. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 254-267.	12.5	360
832	Single-Cell RNA Sequencing Reveals the Altered Landscape of Immune Cells in Immune Checkpoint Inhibitor Related Myocarditis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
833	Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2844-2868.	3.3	43
834	Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease. <i>Tumori</i> , 2022, 108, 609-614.	0.6	3
835	A Meta-Analysis of Efficacy and Safety of PD-1/PD-L1 Inhibitors in Triple-Negative Breast Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-7.	0.6	3
836	Biomarkers and risk factors for the early prediction of immune-related adverse events: a review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	11
837	Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors. <i>Scientific Reports</i> , 2022, 12, 1753.	1.6	4
838	Novel antibodies which have an impact on immune status after allogeneic hematopoietic cell transplantation. <i>Expert Review of Hematology</i> , 2022, , 1-7.	1.0	0
839	Adverse events induced by nivolumab and ipilimumab combination regimens. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110583.	1.4	11
840	A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre. <i>Current Oncology</i> , 2022, 29, 869-880.	0.9	2
841	Immunotherapy Versus Hospice: Treatment Decision-Making in the Modern Era of Novel Cancer Therapies. <i>Current Oncology Reports</i> , 2022, 24, 285-294.	1.8	2
842	Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer. <i>JAMA Oncology</i> , 2022, , .	3.4	0
843	Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2239-2254.	2.0	11

#	ARTICLE	IF	CITATIONS
844	Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series. <i>Cureus</i> , 2022, 14, e22070.	0.2	2
845	A Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 788629.	2.2	6
846	Sinus Node Dysfunction Co-occurring with Immune Checkpoint Inhibitor-associated Myocarditis. <i>Internal Medicine</i> , 2022, 61, 2161-2165.	0.3	8
847	Immune-related neuromuscular junction disorder after immune checkpoint inhibitor treatment. <i>Journal of Cancer Research and Practice</i> , 2022, 9, 22.	0.2	1
848	Strategies to mitigate the toxicity of cancer therapeutics. <i>Advances in Cancer Research</i> , 2022, , 215-244.	1.9	5
849	Neurologic complications of immune modulatory therapy. , 2022, , 537-551.		0
850	ä,è,æŠ—è,žç~çš,,âçžæ•â†æ~æ•âº”ç”ç©¶èž,â±•. <i>Scientia Sinica Vitae</i> , 2022, , .	0.1	1
852	Sick Sinus Syndrome: More Than a Needle-in-a-haystack Manifestation of Immune Checkpoint Inhibitor-associated Myocarditis. <i>Internal Medicine</i> , 2022, , .	0.3	1
853	Thromboembolism Adverse Events Caused by Immune Checkpoint Inhibitor Therapy: A Disproportionality Study from 2010 to 2020 based on FAERS Database. , 2022, , .		0
854	Patient-Reported Outcomes During Checkpoint Inhibition: Insight into Symptom Burden in Daily Clinical Practice. <i>Journal of Pain and Symptom Management</i> , 2022, 63, 997-1005.	0.6	5
855	Rapid Improvement Following Receipt of Infliximab in Steroid-refractory Durvalumab-Associated Grade 3 Pneumonitis. <i>Cureus</i> , 2022, 14, e22295.	0.2	2
856	Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice. <i>Neurological Sciences</i> , 2022, 43, 2339-2361.	0.9	16
857	The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond. <i>Vaccines</i> , 2022, 10, 304.	2.1	2
858	Predictive biomarkers of immune-related adverse events. <i>Voprosy Onkologii</i> , 2022, 68, 29-33.	0.1	0
859	Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2022, 114, 949-958.	0.7	24
860	Immune Checkpoint Inhibitorsâ€”Associated Cardiotoxicity. <i>Cancers</i> , 2022, 14, 1145.	1.7	25
861	Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era. <i>Cells</i> , 2022, 11, 770.	1.8	26
862	Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma. <i>Cancers</i> , 2022, 14, 1248.	1.7	3

#	ARTICLE	IF	CITATIONS
863	Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 331-338.	3.3	16
864	Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology. <i>Current Oncology</i> , 2022, 29, 1828-1839.	0.9	72
865	Acute Liver Failure following a Single Dose of Atezolizumab, as Assessed for Causality Using the Updated RUCAM. <i>Case Reports in Gastrointestinal Medicine</i> , 2022, 2022, 1-4.	0.2	3
866	Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. <i>Gut</i> , 2022, 71, 1412-1425.	6.1	79
867	Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review. <i>Immunotherapy</i> , 2022, , .	1.0	4
868	Primed for toxicity: CD4+ T cells and immune checkpoint inhibitors. <i>Med</i> , 2022, 3, 155-156.	2.2	3
869	Elevated circulating memory T cells precede immunotherapy toxicities in melanoma. <i>Trends in Cancer</i> , 2022, , .	3.8	7
870	Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience. <i>Frontiers in Pharmacology</i> , 2022, 13, 837499.	1.6	1
871	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. <i>Frontiers in Immunology</i> , 2022, 13, 804597.	2.2	27
872	A Case of Lung Cancer with Very-Late-Onset Immune Checkpoint Inhibitor-Related Myocarditis. <i>CJC Open</i> , 2022, 4, 651-655.	0.7	2
873	Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors. <i>Journal of Immunotherapy</i> , 2022, 45, 210-216.	1.2	15
874	Post-hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors. <i>Health Science Reports</i> , 2022, 5, e536.	0.6	2
875	Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis. <i>Cardio-Oncology</i> , 2022, 8, 5.	0.8	8
876	Radiation-induced enterocolitis after combination therapy with palliative radiotherapy and immune checkpoint inhibitors in patients with metastatic lung cancer. <i>Experimental and Therapeutic Medicine</i> , 2022, 23, 336.	0.8	2
877	Protective Effect of Crocin on Immune Checkpoint Inhibitors-Related Myocarditis Through Inhibiting NLRP3 Mediated Pyroptosis in Cardiomyocytes via NF- κ B Pathway. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 1653-1666.	1.6	15
878	Immunotherapy in cancer: A review. <i>IP International Journal of Comprehensive and Advanced Pharmacology</i> , 2022, 7, 27-29.	0.1	0
879	Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment. <i>Journal of Immunology Research</i> , 2022, 2022, 1-9.	0.9	20
880	Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. <i>Frontiers in Oncology</i> , 2022, 12, 836859.	1.3	25

#	ARTICLE	IF	CITATIONS
882	Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions. <i>Seminars in Cancer Biology</i> , 2022, 86, 532-541.	4.3	14
883	Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience. <i>Diagnostics</i> , 2022, 12, 685.	1.3	1
884	Targeting HIF-1 α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	42
885	PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases. <i>Frontiers in Pharmacology</i> , 2022, 13, 854967.	1.6	10
886	Acquired Hemophilia as a Paraneoplastic Syndrome in a Patient With Small Cell Lung Carcinoma. <i>Cureus</i> , 2022, 14, e23926.	0.2	1
887	PD-1/L1 inhibitors may increase the risk of pericardial disease in non-small-cell lung cancer patients: a meta-analysis and systematic review. <i>Immunotherapy</i> , 2022, , .	1.0	2
888	Nivolumab Combined With Ipilimumab Treatment Induced Hypophysitis and Immune-Mediated Liver Injury in Advanced Esophageal Squamous Cell Carcinoma: A Case Report. <i>Frontiers in Oncology</i> , 2022, 12, 801924.	1.3	1
889	Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism. <i>Frontiers in Immunology</i> , 2022, 13, 830631.	2.2	28
890	Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	5
891	Cannabis suppresses antitumor immunity by inhibiting JAK/STAT signaling in T cells through CNR2. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 99.	7.1	18
892	Rheumatic Complications of Immune Checkpoint Inhibitors. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 411-428.	0.8	3
893	Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients. <i>Clinical Imaging</i> , 2022, 86, 31-37.	0.8	0
894	The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis. <i>Translational Oncology</i> , 2022, 20, 101375.	1.7	15
895	Can Immune-related adverse events serve as clinical biomarkers of PD-1/PD-L1 inhibitor efficacy in Pan-Cancer Patients?. <i>International Immunopharmacology</i> , 2022, 108, 108738.	1.7	1
896	Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events. <i>Cancer Biology and Medicine</i> , 2021, 18, 1118-1133.	1.4	16
897	Formation of necrotizing vasculitis in the patient with diffuse B-cell large cell lymphoma on immune checkpoint inhibitor (PD-1) therapy. <i>HERALD of North-Western State Medical University Named After I I Mechnikov</i> , 2021, 13, 83-90.	0.1	0
898	Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 290-298.	0.5	3
899	Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor. <i>Frontiers in Immunology</i> , 2021, 12, 793831.	2.2	16

#	ARTICLE	IF	CITATIONS
900	Association of advanced age and cancer history with autoimmune disease in melanoma patients: a cross-sectional study. <i>BMC Cancer</i> , 2021, 21, 1300.	1.1	2
902	Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries. <i>Frontiers in Immunology</i> , 2021, 12, 799077.	2.2	7
903	Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: A comprehensive review. <i>World Journal of Experimental Medicine</i> , 2021, 11, 79-92.	0.9	8
904	Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1857-1869.	3.3	9
905	pH Low Insertion Peptide-Modified Programmed Cell Death-Ligand 1 Potently Suppresses T-Cell Activation Under Acidic Condition. <i>Frontiers in Immunology</i> , 2021, 12, 794226.	2.2	2
906	Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China. <i>Thoracic Cancer</i> , 2022, 13, 412-422.	0.8	19
908	Evaluation of free radical scavenging with in vitro antiproliferative properties of different extracts of <i>pluchea lanceolata</i> (dc.) oliv. and <i>hiern</i> in cancer cell lines. <i>Pharmacognosy Magazine</i> , 2021, 17, 886.	0.3	2
909	Electrolyte Abnormalities Associated With The Use of Atezolizumab – A Systematic Review. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2022, 12, 35-44.	0.4	1
910	PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. <i>Frontiers in Pharmacology</i> , 2022, 13, 835510.	1.6	10
911	A roadmap for translational cancer glycoimmunology at single cell resolution. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 143.	3.5	5
912	The use of immunotherapy in older patients with advanced non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2022, 106, 102394.	3.4	16
913	Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews. <i>Drugs</i> , 2022, , .	4.9	3
914	Association of thyroid function abnormality and prognosis in non-small-cell lung cancer patients treated with PD-1 inhibitors. <i>Future Oncology</i> , 2022, 18, 2289-2300.	1.1	2
915	T Cell-Mediated Targeted Delivery of Anti-PD-L1 Nanobody Overcomes Poor Antibody Penetration and Improves PD-L1 Blocking at the Tumor Site. <i>Cancer Immunology Research</i> , 2022, 10, 713-727.	1.6	4
916	Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events. <i>JAMA Network Open</i> , 2022, 5, e227722.	2.8	25
917	Principles of Surgery in Head and Neck Cutaneous Melanoma. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 251-262.	0.4	1
918	Sintilimab for the treatment of non-small cell lung cancer. <i>Biomarker Research</i> , 2022, 10, 23.	2.8	16
920	Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence. <i>Experimental Cell Research</i> , 2022, 416, 113157.	1.2	15

#	ARTICLE	IF	CITATIONS
952	Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2837-2848.	2.0	5
953	Immunotherapy-induced Colitis. <i>Journal of Clinical Gastroenterology</i> , 2022, Publish Ahead of Print, .	1.1	5
954	Histological diversity of anti-PD1-induced colitis.. <i>Histology and Histopathology</i> , 2022, , 18456.	0.5	1
961	Pharmacist's role in immune-related adverse events management: real-world incidence and risk evaluation from immunotherapy. <i>International Journal of Pharmacy Practice</i> , 2022, 30, 377-382.	0.3	2
962	Combined Treatment with Ultrasound and Immune Checkpoint Inhibitors for Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 2448.	1.0	4
963	American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach. <i>Endocrine Practice</i> , 2022, 28, 719-731.	1.1	12
964	Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events. <i>PLoS ONE</i> , 2022, 17, e0267572.	1.1	5
965	Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events. <i>Current Oncology</i> , 2022, 29, 3104-3117.	0.9	4
966	Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer: A single-center observational study. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2022, 9, 100076.	0.7	2
967	Cardio-Oncology Considerations in Oncologic Treatment Decisions. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 237-242.	0.2	0
968	Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2022, 22, 93-102.	0.3	6
969	Real-world data on the incidence of immune-related adverse events associated with anti-PD-1/PD-L1 treatment in Russia. <i>Voprosy Onkologii</i> , 2022, 68, 188-199.	0.1	3
970	Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors. <i>Materials and Design</i> , 2022, 219, 110738.	3.3	0
971	Overcoming resistance to oncolytic virus M1 by targeting PI3K- $\hat{\gamma}$ 3 in tumor associated myeloid cells. <i>Molecular Therapy</i> , 2022, , .	3.7	1
972	Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study. <i>Cancers</i> , 2022, 14, 2276.	1.7	4
974	Hyaluronidase Enhances Targeting of Hydrogel-Encapsulated Anti-CTLA-4 to Tumor Draining Lymph Nodes and Improves Anti-Tumor Efficacy. <i>Gels</i> , 2022, 8, 284.	2.1	3
975	Neurotoxicity as a rare side effect of immune checkpoint inhibitors. A case report and review of the literature. <i>Memo - Magazine of European Medical Oncology</i> , 0, , .	0.3	1
976	Cancer Therapy-Related Cardiac Dysfunction in Patients Treated with a Combination of an Immune Checkpoint Inhibitor and Doxorubicin. <i>Cancers</i> , 2022, 14, 2320.	1.7	4

#	ARTICLE	IF	CITATIONS
977	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. <i>Cancer Cell</i> , 2022, 40, 509-523.e6.	7.7	115
978	Combination Immunotherapy in the First-line Setting for Non-small-cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2022, 62, 75-80.	0.0	0
979	Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review. <i>Cancer Reports</i> , 2022, 5, e1624.	0.6	7
980	Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. <i>Cancers</i> , 2022, 14, 2460.	1.7	2
981	Role of Abdominal and Pelvic CT Scans in Diagnosis of Patients with Immunotherapy-Induced Colitis. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, 5, 32-36.	0.6	1
982	Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 745-766.	1.8	6
983	Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review. <i>Current Cardiology Reviews</i> , 2023, 19, .	0.6	3
984	Low-Salt Diet Reduces Anti-CTLA4 Mediated Systemic Immune-Related Adverse Events while Retaining Therapeutic Efficacy against Breast Cancer. <i>Biology</i> , 2022, 11, 810.	1.3	2
985	Adverse effects under immune checkpoint inhibitors on [18F]FDG PET/CT imaging. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 66, .	0.4	7
986	Immunotherapy toxicities: An SGO clinical practice statement. <i>Gynecologic Oncology</i> , 2022, , .	0.6	1
987	Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	0
988	Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment. <i>Cancers</i> , 2022, 14, 2687.	1.7	10
989	Immune-related adverse events in older adults: Data mining of the FDA Adverse Event Reporting System. <i>Journal of Geriatric Oncology</i> , 2022, , .	0.5	2
990	Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program. <i>Journal of Clinical Oncology</i> , 2022, 40, 3439-3452.	0.8	24
991	Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. <i>Advanced Science</i> , 2022, 9, .	5.6	140
992	Cutaneous melanoma. , 2023, , 370-375.		0
994	Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	15
995	Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	8

#	ARTICLE	IF	CITATIONS
996	Mechanisms underlying immune-related adverse events during checkpoint immunotherapy. <i>Clinical Science</i> , 2022, 136, 771-785.	1.8	2
997	Drug-induced digestive tract injury: decoding some invisible offenders. <i>Human Pathology</i> , 2023, 132, 135-148.	1.1	2
998	The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3107-e3114.	1.8	7
999	Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis. <i>International Journal of Cancer</i> , 2022, 151, 1860-1873.	2.3	19
1000	A Decade of Success in Melanoma Immunotherapy and Targeted Therapy: What Every Radiologist Should Know. <i>Journal of Computer Assisted Tomography</i> , 2022, 46, 621-632.	0.5	2
1001	Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	7
1002	Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor-associated myocarditis. <i>Cancer Communications</i> , 2022, 42, 902-905.	3.7	5
1003	Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	13
1004	Case Report: Acute Myocarditis Due to PD-L1 Inhibitor Durvalumab Monotherapy in a Patient With Lung Squamous Cell Carcinoma. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
1005	Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1078-1085.	0.5	5
1006	Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin's Lymphoma. <i>Cancers</i> , 2022, 14, 2936.	1.7	4
1007	Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab. , 2022, 10, e004378.		4
1008	Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. , 2022, 10, e004670.		21
1009	γ H2AX, a DNA Double-Strand Break Marker, Correlates with PD-L1 Expression in Smoking-Related Lung Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6679.	1.8	4
1010	Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
1011	Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. <i>World Journal of Clinical Oncology</i> , 2022, 13, 448-472.	0.9	6
1012	Immune Checkpoint Inhibitor Associated Autoimmune Encephalitis, Rare and Novel Topic of Neuroimmunology: A Case Report and Review of the Literature. <i>Brain Sciences</i> , 2022, 12, 773.	1.1	7
1013	Myocardial Dysfunction in Patients with Cancer. <i>Heart Failure Clinics</i> , 2022, 18, 361-374.	1.0	1

#	ARTICLE	IF	CITATIONS
1014	Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram. <i>Lung Cancer</i> , 2022, 170, 74-84.	0.9	7
1015	Treatment-Related Adverse Events of PD-1 or PD-L1 Inhibitors for Triple Negative Breast Cancer Patients: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1016	Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
1017	Research progress on immunotherapy in triple-negative breast cancer (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	9
1018	Immune checkpoint inhibitor-related liver toxicity. <i>Clinical Liver Disease</i> , 2022, 20, 93-96.	1.0	0
1019	Monitoring Endocrine Complications of Immunotherapy: A Screening Tool. <i>Cureus</i> , 2022, , .	0.2	3
1020	Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1021	The predictive potential of autoimmune-inflammatory syndrome induced by adjuvants (ASIA) criteria to assess the risk of adverse events and efficacy of immune checkpoint inhibitor therapy. <i>Immunologic Research</i> , 2022, 70, 765-774.	1.3	1
1022	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 861-874.	1.1	6
1023	Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
1024	Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1445-1452.	0.5	17
1025	Adverse drug reactions associated with immune checkpoint inhibitors: an exploratory nested case-control study in a historical cohort. <i>Therapie</i> , 2022, , .	0.6	0
1027	Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1028	Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy. <i>Journal of Immunology</i> , 2022, 209, 696-709.	0.4	14
1029	Immune checkpoint inhibitor-related pneumonitis: Acute lung injury with rapid progression and organizing pneumonia with less severe clinical disease. <i>Histopathology</i> , 0, , .	1.6	4
1030	Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system. <i>International Immunopharmacology</i> , 2022, 110, 109015.	1.7	4
1031	Recent progresses on radiotherapeutics-based treatment of cancer with two-dimensional nanomaterials. <i>Applied Materials Today</i> , 2022, 29, 101584.	2.3	1
1032	Immunotherapy-induced Hepatotoxicity: A Review. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3

#	ARTICLE	IF	CITATIONS
1033	Right ventricular and atrial strain in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy. <i>ESC Heart Failure</i> , 2022, 9, 3533-3542.	1.4	3
1034	Application of emetine in SARS-CoV-2 treatment: regulation of p38 MAPK signaling pathway for preventing emetine-induced cardiac complications. <i>Cell Cycle</i> , 2022, 21, 2379-2386.	1.3	11
1035	Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologistsâ€™ Perspectives. <i>Middle East Journal of Digestive Diseases</i> , 2022, 14, 244-253.	0.2	1
1036	Clinical Outcomes after Immunotherapies in Cancer Setting during COVID-19 Era: A Systematic Review and Meta-Regression. <i>Reports</i> , 2022, 5, 31.	0.2	0
1037	Serum immunoglobulins might be useful predictors of immune-related adverse events after immune checkpoint inhibitor usage in lung cancer. <i>Thoracic Cancer</i> , 0, , .	0.8	3
1038	Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	9
1039	Peripheral Blood Biomarkers Predictive of Efficacy Outcome and Immune-Related Adverse Events in Advanced Gastrointestinal Cancers Treated with Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 3736.	1.7	7
1040	Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1043	Camrelizumab-Related Lethal Arrhythmias and Myasthenic Crisis in a Patient with Metastatic Thymoma. <i>Case Reports in Cardiology</i> , 2022, 2022, 1-6.	0.1	5
1044	The â€false hopeâ€™ argument in discussions on expanded access to investigational drugs: a critical assessment. <i>Medicine, Health Care and Philosophy</i> , 2022, 25, 693-701.	0.9	1
1045	Biologic Therapy for Refractory Immune Checkpoint Inhibitor Colitis. <i>Biologics: Targets and Therapy</i> , 0, Volume 16, 119-127.	3.0	1
1046	Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab. <i>Liver Cancer</i> , 2022, 11, 572-575.	4.2	2
1047	Checking ovarian reserves after checkpoint blockade. <i>Nature Cancer</i> , 2022, 3, 907-908.	5.7	3
1048	Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 591-598.	2.0	4
1049	Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors. <i>Journal of Cardiology</i> , 2023, 81, 63-67.	0.8	8
1050	Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1051	Cardiovascular adverse events induced by immune checkpoint inhibitors: A real world study from 2018 to 2022. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	6
1052	Clinical course and management of insidious adrenal crisis manifested initially as hyperpyrexia secondary to pembrolizumab: Case reports and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2

#	ARTICLE	IF	CITATIONS
1053	Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1054	Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry. <i>European Journal of Cancer</i> , 2022, 177, 197-205.	1.3	8
1055	The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	1
1056	Pancancer analysis of a potential gene mutation model in the prediction of immunotherapy outcomes. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
1057	Immune checkpoint inhibitors increase the risk of kidney transplant rejection: a real-world pharmacovigilance study. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 231-235.	1.0	3
1058	Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study. <i>European Journal of Cancer</i> , 2022, 174, 113-120.	1.3	9
1059	Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>Cancers</i> , 2022, 14, 4494.	1.7	16
1060	The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1061	Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor. <i>Immunotherapy</i> , 2022, 14, 1097-1107.	1.0	3
1062	Research progress of neoantigens in gynecologic cancers. <i>International Immunopharmacology</i> , 2022, 112, 109236.	1.7	5
1063	Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. <i>Theranostics</i> , 2022, 12, 6106-6129.	4.6	14
1064	Hepatology (Liver and Bile Duct). , 2022, , 119-165.		0
1065	Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy. <i>Internal Medicine</i> , 2023, 62, 1319-1322.	0.3	3
1066	Immunotherapy Adverse Events. <i>Current Clinical Pathology</i> , 2022, , 25-30.	0.0	0
1067	Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist. <i>Current Clinical Pathology</i> , 2022, , 91-111.	0.0	0
1068	Cardiology (Heart). , 2022, , 7-27.		0
1069	Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy. <i>Journal of Cancer</i> , 2022, 13, 3091-3102.	1.2	4
1070	Diagnostic Methods of Cardiac Immunotherapy Damaging. <i>Current Clinical Pathology</i> , 2022, , 51-61.	0.0	0

#	ARTICLE	IF	CITATIONS
1071	Rational development of molecularly imprinted nanoparticles for blocking PD-1/PD-L1 axis. <i>Chemical Science</i> , 2022, 13, 10897-10903.	3.7	8
1072	Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody. <i>Cancer Control</i> , 2022, 29, 107327482211112.	0.7	17
1073	<i>Pulmonology (Lung)</i> , 2022, , 275-299.		1
1074	Evaluation and Management of Acute High-Grade Immunotherapy-Related Neurotoxicity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1075	Management of Patients with Cardiac Toxicity: The Point of View of the Cardiologist. <i>Current Clinical Pathology</i> , 2022, , 73-89.	0.0	0
1076	Intracellular Cardiac Signaling Pathways Altered by Cancer Therapies. , 2022, , 111-173.		0
1077	Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	13
1078	Role of Endomyocardial Biopsy in Diagnostics of Myocarditis. <i>Diagnostics</i> , 2022, 12, 2104.	1.3	6
1079	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. <i>Cancers</i> , 2022, 14, 4192.	1.7	6
1080	Cardiovascular Outcomes and Hospitalizations in Asian Patients Receiving Immune Checkpoint Inhibitors: A Population-based Study. <i>Current Problems in Cardiology</i> , 2023, 48, 101380.	1.1	24
1081	Efficacy and Safety of Pembrolizumab Monotherapy for Recurrent/Unresectable/Metastatic Oral Squamous Cell Carcinoma: A Single-Center Study in China. <i>Journal of Oncology</i> , 2022, 2022, 1-8.	0.6	1
1082	Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
1083	Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1084	Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-10.	1.1	0
1085	Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer. <i>Joint Bone Spine</i> , 2023, 90, 105457.	0.8	3
1086	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1087	Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit. <i>Journal of Clinical Medicine</i> , 2022, 11, 5611.	1.0	5
1088	Toxic epidermal necrolysis after immune checkpoint inhibition, case report, and review of the literature. <i>Acta OncolÁgica</i> , 2022, 61, 1295-1299.	0.8	2

#	ARTICLE	IF	CITATIONS
1089	Immune checkpoint inhibitors – the revolutionary cancer immunotherapy comes with a cardiotoxic price. <i>Trends in Cardiovascular Medicine</i> , 2024, 34, 71-77.	2.3	6
1090	Chinese expert consensus on diagnosis and treatment of radiation pneumonitis. <i>Precision Radiation Oncology</i> , 2022, 6, 262-271.	0.4	2
1091	Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 1370-1382.	1.9	8
1092	Immune-related pneumonitis requiring low-dose prednisone maintenance in one patient with durable complete response. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 986-991.	0.5	2
1093	Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. <i>European Journal of Endocrinology</i> , 2022, 187, G1-G21.	1.9	35
1094	A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 2911-2914.	0.8	6
1095	Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1096	Long-Term Cardiovascular Mortality among 80,042 Older Patients with Bladder Cancer. <i>Cancers</i> , 2022, 14, 4572.	1.7	4
1097	Myocarditis Induced by Immunotherapy in Metastatic Melanoma – Review of Literature and Current Guidelines. <i>Journal of Clinical Medicine</i> , 2022, 11, 5182.	1.0	2
1098	Application of artificial liver in immune-related liver injury induced by immune checkpoint inhibitor: Case reports and review of the literature. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1099	Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2235-2242.	1.2	4
1100	Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1101	Therapeutic strategies for gastric cancer targeting immune cells: Future directions. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
1102	Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series. <i>Melanoma Research</i> , 2022, 32, 451-459.	0.6	3
1103	Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
1104	Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1428-1442.	1.3	1
1105	An exploratory cross-sectional study of immune checkpoint inhibitors and immuno-related adverse events: Knowledge and influencing factors among Japanese oncology nurses. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2023, 10, 100147.	0.7	3
1106	Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single-center case series. <i>Cancer Medicine</i> , 0, , .	1.3	6

#	ARTICLE	IF	CITATIONS
1107	Anti-PD-1 immune checkpoint inhibitor inducing endocrine toxicity in a patient with advanced lung cancer: A case report and literature review. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	3
1108	Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis. , 2022, 10, e005323.		16
1109	The role of immune checkpoints in cardiovascular disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	10
1110	Circulating biomarkers of response to immunotherapy and immune-related adverse events. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 855-865.	1.5	2
1111	Cancer metastasis chemoprevention prevents circulating tumour cells from germination. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	9
1112	Pathogenesis of Immune Checkpoint Inhibitor-Mediated Colitis. <i>Advances in Clinical Medicine</i> , 2022, 12, 8888-8893.	0.0	0
1113	A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
1114	Evaluation of Knowledge of Immunotherapy Toxicities Among Emergency Physicians in Riyadh, Saudi Arabia. <i>Cureus</i> , 2022, , .	0.2	0
1115	Teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: a case report. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211332.	0.4	2
1116	The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 1389-1398.	0.6	11
1118	PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1119	MITF Is Regulated by Redox Signals Controlled by the Selenoprotein Thioredoxin Reductase 1. <i>Cancers</i> , 2022, 14, 5011.	1.7	2
1121	Imaging of Drug-Related Pneumonitis in Oncology. <i>Seminars in Respiratory and Critical Care Medicine</i> , 0, , .	0.8	0
1122	Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 1275-1287.	1.0	4
1123	Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers. <i>Onc Immunology</i> , 2022, 11, .	2.1	14
1124	Myocarditis-myositis-myasthenia gravis overlap syndrome depending on immune checkpoint inhibitor. <i>Journal of Neurosciences in Rural Practice</i> , 0, .	0.3	0
1125	Clinical cancer immunotherapy: Current progress and prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	39
1126	Immune-Checkpoint-Inhibitor Therapy—Principles and Relevance of Biomarkers for Pathologists and Oncologists. <i>Advances in Anatomic Pathology</i> , 0, Publish Ahead of Print, .	2.4	0

#	ARTICLE	IF	CITATIONS
1127	Clustering using unsupervised machine learning can stratify the risk of immune-related liver injury. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 0, , .	1.4	2
1128	Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma. <i>JAMA Oncology</i> , 2022, 8, 1794.	3.4	33
1129	Quality and content evaluation of websites with information about immune checkpoint inhibitors: An environmental scan. <i>PLoS ONE</i> , 2022, 17, e0275676.	1.1	1
1130	Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 4933.	1.7	5
1131	Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2022, 33, 1217-1238.	0.6	204
1132	Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1777-1792.	1.3	6
1133	Limitations of Immunotherapy in Cancer. <i>Cureus</i> , 2022, , .	0.2	2
1134	Progress in diagnosis and treatment of checkpoint inhibitor pneumonitis. <i>Current Opinion in Oncology</i> , 2023, 35, 31-36.	1.1	0
1135	Tbc1d10c is a selective, constitutive suppressor of the CD8 T-cell anti-tumor response. <i>Onc Immunology</i> , 2022, 11, .	2.1	3
1136	Immune Checkpoint Inhibitors Related to Cardiotoxicity. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 378.	0.8	3
1137	Applying quantitative CMR parameters for detecting myocardial lesion in immune checkpoint inhibitors-associated myocarditis. <i>European Journal of Radiology</i> , 2022, 156, 110558.	1.2	0
1138	Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do. <i>Cancers</i> , 2022, 14, 5403.	1.7	7
1139	Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-“Small Cell Lung Cancer. <i>Radiographics</i> , 2022, 42, 1956-1974.	1.4	4
1140	Nanomedicine for advanced cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 351, 1017-1037.	4.8	7
1141	Reactivation of immune-related colitis during targeted therapy in a patient with metastatic cutaneous melanoma. <i>Siberian Journal of Oncology</i> , 2022, 21, 162-167.	0.1	1
1142	A Review of Immune Checkpoint Blockade for the General Surgeon. <i>Journal of Surgical Research</i> , 2023, 281, 289-298.	0.8	3
1143	Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2023, 14, 73-80.	0.8	3
1144	PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2

#	ARTICLE	IF	CITATIONS
1145	T cells specific for β -myosin drive immunotherapy-related myocarditis. <i>Nature</i> , 2022, 611, 818-826.	13.7	100
1146	Artificial intelligence for prediction of response to cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2022, 87, 137-147.	4.3	12
1147	Immune-related keratitis is a rare complication associated with nivolumab treatment in a patient with advanced colorectal cancer: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1149	Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives. <i>Cancers</i> , 2022, 14, 5489.	1.7	4
1151	Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
1152	Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course. <i>Cancer</i> , 2023, 129, 367-375.	2.0	4
1154	The novel diagnostic index based on HLA-DRB1 genotype and PD-L1 expression can predict severe irAEs in patients with metastatic melanoma taking immune checkpoint inhibitors. <i>Critical Reviews in Immunology</i> , 2022, , .	1.0	0
1155	Oncologic Emergencies: Pathophysiology, Diagnosis, and Initial Management. , 2022, , .		0
1156	A Review of Neurotoxicities Associated with Immune Checkpoint Inhibitors. , 2022, , 1-16.		0
1157	Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. <i>American Journal of Gastroenterology</i> , 2022, 117, 1917-1932.	0.2	4
1158	Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 2289-2305.	1.3	6
1159	Cardiotoxicidade associada aos inibidores de checkpoint: relato de caso. <i>Brazilian Journal of Health Review</i> , 2022, 5, 23192-23203.	0.0	0
1160	Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma. <i>Cancers</i> , 2022, 14, 5676.	1.7	3
1161	Multisystem immune-related adverse events due to toripalimab: Two cases-based review. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
1162	Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report. <i>Medicine (United States)</i> , 2022, 101, e31873.	0.4	4
1163	Changes of IL-6 And IFN- γ before and after the adverse events related to immune checkpoint inhibitors: A retrospective study. <i>Medicine (United States)</i> , 2022, 101, e31761.	0.4	2
1164	The immunological mechanisms and therapeutic potential in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	7
1165	Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4

#	ARTICLE	IF	CITATIONS
1166	Supportive Care and Palliative Care for Lung Cancer in Long-term Survival Era. Japanese Journal of Lung Cancer, 2022, 62, 927-930.	0.0	0
1167	Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells. Frontiers in Immunology, 0, 13, .	2.2	4
1168	Checkpoint inhibitors are a basic scienceâ€based, transformative new treatment for lung cancer. Respirology, 2023, 28, 101-106.	1.3	2
1169	Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. BMC Cancer, 2022, 22, .	1.1	1
1170	Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity. Npj Genomic Medicine, 2022, 7, .	1.7	8
1172	LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice. JACC: CardioOncology, 2022, 4, 635-645.	1.7	4
1173	Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society. Endocrinology and Metabolism, 2022, 37, 839-850.	1.3	3
1174	Germline variants associated with toxicity to immune checkpoint blockade. Nature Medicine, 2022, 28, 2584-2591.	15.2	38
1175	Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
1176	Approach to the Patient With Immune Checkpoint Inhibitorâ€Associated Endocrine Dysfunction. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 1514-1525.	1.8	8
1177	Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitorâ€Induced Myocarditis. JACC: CardioOncology, 2022, 4, 689-700.	1.7	19
1178	Unchecked autoreactive CD8+ T cells wreak havoc in cancer immunotherapy. , 2022, 1, 1111-1113.		2
1179	Immune-related adverse events: A bibliometric analysis. Frontiers in Immunology, 0, 13, .	2.2	10
1181	Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis. Targeted Oncology, 2023, 18, 147-158.	1.7	2
1182	Cutaneous adverse events in lung cancer patients on the therapy based on PD-1/PD-L1 inhibitors: A prospective observational cohort study. Current Problems in Cancer, 2022, , 100934.	1.0	0
1183	Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment. BMJ Case Reports, 2022, 15, e251966.	0.2	4
1184	A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?. JACC: CardioOncology, 2022, 4, 670-672.	1.7	1
1185	Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation. JACC: CardioOncology, 2022, 4, 727-730.	1.7	6

#	ARTICLE	IF	CITATIONS
1186	Immune Checkpoint Inhibitor Myocarditis—Treatment Strategies and—Future Directions. <i>JACC: CardioOncology</i> , 2022, 4, 704-707.	1.7	12
1187	Multidisciplinary treatment of a patient with severe immune checkpoint inhibitor-induced colitis: A case report. <i>World Journal of Clinical Cases</i> , 0, 10, 13108-13114.	0.3	1
1188	Pembrolizumab induced remission of recurrent and metastatic sinonasal squamous cell carcinoma after overcoming checkpoint—inhibitor pneumonitis: A case report and literature review. <i>Cancer Reports</i> , 0, , .	0.6	3
1189	Reactivation of natural killer cells with monoclonal antibodies in the microenvironment of malignant neoplasms. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
1190	Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	13
1191	Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies. <i>Frontiers in Veterinary Science</i> , 0, 9, .	0.9	4
1192	Late—onset immune checkpoint inhibitor—related pneumonitis after cessation of sintilimab: A case report and literature review. <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	0.8	1
1193	Microbiome influencers of checkpoint blockade—associated toxicity. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	13
1194	Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1195	Neutrophil elastase: From mechanisms to therapeutic potential. <i>Journal of Pharmaceutical Analysis</i> , 2023, 13, 355-366.	2.4	11
1196	Metabolic landscape dysregulation in bronchoalveolar lavage fluid of checkpoint inhibitor pneumonitis. <i>Clinical Immunology</i> , 2023, 247, 109230.	1.4	1
1197	Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors. <i>Hepatology Research</i> , 2023, 53, 450-459.	1.8	2
1198	A New Look at Cancer Immunotherapy via Artificial Intelligence. , 2023, , 1-18.		0
1199	Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. <i>Vaccines</i> , 2023, 11, 101.	2.1	14
1200	The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1201	Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies—pharmacovigilance database analysis with real-world data validation. <i>BMC Medicine</i> , 2023, 21, .	2.3	2
1202	Microbiota in Cancer Immunotherapy: The Next Milestone of Immuno-oncology?. , 2023, , 269-287.		1
1203	The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity. <i>Translational Oncology</i> , 2023, 28, 101619.	1.7	8

#	ARTICLE	IF	CITATIONS
1204	Checkpoint inhibitor induced myositis – The value of MRI STIR. <i>ENeurologicalSci</i> , 2023, 30, 100442.	0.5	3
1205	Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study. <i>Cancers</i> , 2023, 15, 240.	1.7	5
1206	Methodological Approaches to Studying Fatal Adverse Drug Reactions. <i>Safety and Risk of Pharmacotherapy</i> , 2022, 10, 381-395.	0.1	0
1207	Incidence of adverse cardiovascular events associated with immune checkpoint inhibitors and risk factors for left ventricular dysfunction: A single-center prospective clinical study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	6
1208	A bibliometric analysis of research progress on pharmacovigilance and cancer from 2002 to 2021. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
1209	Evaluating Pneumonitis Incidence in Patients with Non-small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data. <i>Cancer Research Communications</i> , 2023, 3, 258-266.	0.7	0
1210	Impact of Immune-Related Adverse Events on Immune Checkpoint Inhibitors Treated Cancer Patients – Survival: Single Center Experience and Literature Review. <i>Cancers</i> , 2023, 15, 888.	1.7	5
1211	Immune Checkpoint Inhibitor-Induced Primary Hyperparathyroidism in a Small-Cell Lung Cancer Patient: A Case Report. <i>Medicina (Lithuania)</i> , 2023, 59, 215.	0.8	2
1212	Pulmonary Side Effects of Immunotherapy. , 2023, , 1-13.		0
1213	Fulminant Myocarditis Complicated with Immune Checkpoint Inhibitor in Patients with Thymoma: Report of Three Cases. <i>International Journal of Cardiovascular Practice</i> , 2023, 7, .	0.2	0
1214	Ex Vivo Blockade of the PD-1 Pathway Improves Recall IFN ^γ Responses of HIV-Infected Persons on Antiretroviral Therapy. <i>Vaccines</i> , 2023, 11, 211.	2.1	0
1215	Case report: A rare case of sintilimab-induced gastric stenosis and literature review. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1217	Enhancer RNA-based modeling of adverse events and objective responses of cancer immunotherapy reveals associated key enhancers and target genes. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1218	Immune-Related Adverse Events of the Gastrointestinal System. <i>Cancers</i> , 2023, 15, 691.	1.7	1
1219	Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers – Emerging Strategies for Clinical Management. <i>Transplantation</i> , 2023, 107, 1452-1462.	0.5	7
1220	Primary cemiplimab treatment for orbital squamous cell carcinoma is effective and may alleviate the need for orbital exenteration. <i>Eye</i> , 2023, 37, 2482-2487.	1.1	7
1221	Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	3
1222	Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System. <i>Clinical Therapeutics</i> , 2023, 45, 151-159.	1.1	3

#	ARTICLE	IF	CITATIONS
1223	Association between <sc>PD</sc> Æ inhibitorÆ related adverse events and frailty assessed by frailty index in lung cancer patients. <i>Cancer Medicine</i> , 0, , .	1.3	1
1224	Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database. <i>Cancer Medicine</i> , 0, , .	1.3	4
1225	Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2169-2178.	2.0	1
1226	Cardiovascular, Renal and Pulmonary Toxicity of Immune Checkpoint Inhibitors in Cancer: What the GP Should Know. <i>Praxis</i> , 2023, 112, 160-171.	0.2	1
1227	A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
1228	Imaging Recommendations for Diagnosis, Staging and Management of Treatment-Related Complications in Cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, , .	0.1	0
1229	Anthracycline Therapy Modifies Immune Checkpoint Signaling in the Heart. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6052.	1.8	2
1230	Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis. <i>Current Oncology Reports</i> , 2023, 25, 743-751.	1.8	2
1231	Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2023, 18, 896-906.	0.5	3
1232	Surgery in the Era of Immunotherapy for Advanced Head and Neck Non-melanoma Skin Cancer. <i>Current Oncology Reports</i> , 2023, 25, 735-742.	1.8	3
1233	Highlights into historical and current immune interventions for cancer. <i>International Immunopharmacology</i> , 2023, 117, 109882.	1.7	2
1234	Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors. <i>Medical Clinics of North America</i> , 2023, 107, 623-640.	1.1	0
1235	Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors. <i>European Journal of Cancer</i> , 2023, 184, 124-136.	1.3	7
1236	Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma. <i>International Immunopharmacology</i> , 2023, 119, 110158.	1.7	2
1237	Has the advent of modern adjuvant systemic therapy for melanoma rendered sentinel node biopsy unnecessary?. <i>European Journal of Cancer</i> , 2023, 186, 166-171.	1.3	7
1238	Recent Developments in the Management of Orbital and Periocular Neoplasms. , 2022, , 311-325.		0
1239	Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. <i>Med</i> , 2023, 4, 113-129.e7.	2.2	31
1240	Immune checkpoint inhibitor-induced aplastic anaemia: Case series and large-scale pharmacovigilance analysis. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1

#	ARTICLE	IF	CITATIONS
1241	Melanome der Haut und Schleimhaut. , 2022, , 205-236.		0
1242	Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy. International Journal of Molecular Sciences, 2023, 24, 2769.	1.8	7
1243	HÄmatologische Neoplasien und solide Tumore. , 2022, , 85-151.		0
1244	Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis. Journal of the Endocrine Society, 2023, 7, .	0.1	8
1245	A Novel Workflow to Create a Checkpoint Inhibitor Pneumonitis Patient Registry. Cureus, 2023, , .	0.2	0
1246	Evaluation of Cardiac Adverse Events with Nivolumab Using a Japanese Real-World Database. Clinical Drug Investigation, 2023, 43, 177-184.	1.1	2
1247	Association of Clinical and Radiological Features with Disease Severity of Symptomatic Immune Checkpoint Inhibitor-Related Pneumonitis. Diagnostics, 2023, 13, 691.	1.3	1
1248	Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis. World Journal of Gastrointestinal Oncology, 0, 15, 352-367.	0.8	0
1249	<it>Salmonella typhimurium</it> may support cancer treatment: a review. Acta Biochimica Et Biophysica Sinica, 2023, 55, 331-342.	0.9	2
1250	Evaluation and management of acute high-grade immunotherapy-related neurotoxicity. Heliyon, 2023, 9, e13725.	1.4	0
1251	Cellular Atlas of Senescent Lineages in Radiation- or Immunotherapy-Induced Lung Injury by Single-Cell RNA-Sequencing Analysis. International Journal of Radiation Oncology Biology Physics, 2023, 116, 1175-1189.	0.4	3
1252	Case report: Electrocardiographic changes in pembrolizumab-induced fatal myocarditis. Frontiers in Immunology, 0, 14, .	2.2	2
1253	Peripheral nervous system adverse events associated with immune checkpoint inhibitors. Journal of Neurology, 2023, 270, 2975-2986.	1.8	3
1254	How Biology Guides the Combination of Locoregional Interventional Therapies and Immunotherapy for Hepatocellular Carcinoma: Cytokines and Their Roles. Cancers, 2023, 15, 1324.	1.7	1
1255	The mechanism and treatment of targeted anti-tumour drugs induced cardiotoxicity. International Immunopharmacology, 2023, 117, 109895.	1.7	3
1256	Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study. Oncologist, 2023, 28, e379-e390.	1.9	4
1257	Advances in immune checkpoint inhibitors induced-cardiotoxicity. Frontiers in Immunology, 0, 14, .	2.2	2
1258	Imaging assessment of toxicity related to immune checkpoint inhibitors. Frontiers in Immunology, 0, 14, .	2.2	6

#	ARTICLE	IF	CITATIONS
1259	Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. <i>Cancer Discovery</i> , 2023, 13, 1100-1115.	7.7	40
1260	Mechanisms of Immunological Toxicity in Cancer Immunotherapy with Checkpoint Inhibitors. , 2023, , 1-18.		0
1261	Phase I Study of a Multivalent WT1 Peptide Vaccine (Galipepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission. <i>Cancers</i> , 2023, 15, 1458.	1.7	3
1262	Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4 and PD-1 targeted immunotherapy. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	4
1263	Endocrine and Neurological Toxicities of Immunotherapies. <i>Praxis</i> , 2023, 112, 178-183.	0.2	1
1265	Management of the adverse effects of cancer immunotherapy with a focus on the respiratory and nervous systems. <i>Journal of the Korean Medical Association</i> , 2023, 66, 116-122.	0.1	0
1266	Immunotherapy and Gastrointestinal Toxicities. <i>Praxis</i> , 2023, 112, 172-177.	0.2	1
1267	Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2217-2231.	2.0	2
1268	The interplay between the microbiome and colonic immune system in checkpoint inhibitor therapy. , 0, 2, .		0
1269	Stuttering as a signal of encephalopathy associated with toripalimab in a pancreatic ductal adenocarcinoma patient: a case report. <i>BMC Neurology</i> , 2023, 23, .	0.8	1
1271	Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1273	Eosinophil and IFN- γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
1274	Current landscape and tailored management of immune-related adverse events. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
1275	Treatment and outcomes of immune checkpoint inhibitors-associated colitis/diarrhea: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2023, 55, 1621-1631.	0.4	1
1276	Supply chain agility and performance: evidence from a meta-analysis. <i>International Journal of Operations and Production Management</i> , 2023, 43, 1587-1633.	3.5	4
1277	Immune-induced pneumonia in patients with advanced solid tumors treated with immunotherapy: a real-world assessment. <i>Future Oncology</i> , 2023, 19, 259-270.	1.1	1
1278	Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations. <i>Oncolimmunology</i> , 2023, 12, .	2.1	0
1279	Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review. <i>Oncology and Therapy</i> , 0, , .	1.0	0

#	ARTICLE	IF	CITATIONS
1280	Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	6
1281	Assessment of Symptoms and Adverse Events Related to Immunotherapy in Patients With Cancer: An Integrative Review. <i>Journal of Pain and Symptom Management</i> , 2023, , .	0.6	0
1282	Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management. <i>Revue Neurologique</i> , 2023, 179, 506-515.	0.6	5
1283	Safety analysis of antineoplastic drugs for lung cancer: a retrospective analysis based on Shaanxi Province in Western China. <i>Expert Opinion on Drug Safety</i> , 2024, 23, 99-105.	1.0	1
1284	Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review. <i>Biology</i> , 2023, 12, 472.	1.3	2
1285	Immunotherapies for advanced hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
1286	Two Cases of Immune Checkpoint Inhibitor-Induced Myocarditis With Complete Atrioventricular Block. <i>Cureus</i> , 2023, , .	0.2	0
1287	Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
1288	Toxicity When Combining Immunotherapy and Radiotherapy. , 2023, , 1-32.		0
1289	Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus. <i>European Journal of Cancer</i> , 2023, 187, 36-57.	1.3	1
1290	Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance. <i>Cardio-Oncology</i> , 2023, 9, .	0.8	1
1291	Gastrointestinal Side Effects of Anticancer Therapy. , 2023, , 1-36.		0
1292	Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases. <i>Diagnostics</i> , 2023, 13, 1243.	1.3	9
1293	Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
1294	Immunotherapy for the treatment of hepatocellular carcinoma: finally in clinical practice. <i>Hepatobiliary Surgery and Nutrition</i> , 2023, 12, 252-255.	0.7	0
1295	Checkpoint Inhibitor Colitis With Superimposed <i>Clostridioides difficile</i> Infection. <i>Cureus</i> , 2023, , .	0.2	0
1296	A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors. <i>European Clinical Respiratory Journal</i> , 2023, 10, .	0.7	1
1297	Effect of age on the risk of immune-related adverse events in patients receiving immune checkpoint inhibitors. <i>Clinical and Experimental Medicine</i> , 2023, 23, 3907-3918.	1.9	5

#	ARTICLE	IF	CITATIONS
1298	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. <i>Journal of Clinical Apheresis</i> , 2023, 38, 77-278.	0.7	81
1299	Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma. <i>Cancers</i> , 2023, 15, 2170.	1.7	0
1300	Immune Responses to Solid Tumors and Immune Checkpoint Therapy. , 2023, , 1028-1041.		0
1301	Hepatic Injury due to Drugs, Dietary and Herbal Supplements, Chemicals and Toxins. , 2024, , 726-841.		0
1302	Administration of immune checkpoint inhibitors at rural towns using the Teleoncology model of care – A North Queensland perspective. <i>Australian Journal of Rural Health</i> , 0, , .	0.7	0
1303	Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients – The European MelSkinTox study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, 1606-1615.	1.3	3
1305	Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
1306	A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	3
1307	The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
1308	Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and Colitis. <i>Cancers</i> , 2023, 15, 2329.	1.7	1
1309	The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 2319.	1.7	1
1310	PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS). <i>Expert Opinion on Drug Safety</i> , 2024, 23, 257-267.	1.0	0
1311	Immune Checkpoint Inhibitors – The Need for Innovation. <i>New England Journal of Medicine</i> , 2023, 388, 1529-1532.	13.9	7
1312	Mortality associated with the development of acute liver failure after a single dose of nivolumab. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	1
1313	Immune-related adverse events following checkpoint inhibitor treatment in head and neck cancers: A comprehensive review. , 2023, 6, 100036.		4
1314	Drawbacks of immune checkpoint inhibition and rigorous management for immune-related adverse events along with a mathematical model to assess therapy success and optimum therapy duration and a strategy against tumor plasticity. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
1315	Added diagnostic value of routinely measured hematology variables in diagnosing immune checkpoint inhibitor mediated toxicity in the emergency department. <i>Cancer Medicine</i> , 2023, 12, 12462-12469.	1.3	1
1316	Risk Factors for Immune Checkpoint Inhibitor – Mediated Cardiovascular Toxicities. <i>Current Oncology Reports</i> , 2023, 25, 753-763.	1.8	3

#	ARTICLE	IF	CITATIONS
1317	Clinical and molecular overview of immunotherapeutic approaches for malignant skin melanoma: Past, present and future. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 186, 103988.	2.0	2
1318	Extensive CardioVascular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study. <i>Pharmaceuticals</i> , 2023, 16, 625.	1.7	1
1319	Evaluating the effect of PD-1 inhibitors on left ventricular function in lung cancer with noninvasive myocardial work. <i>Quantitative Imaging in Medicine and Surgery</i> , 2023, .	1.1	1
1330	Case Report: Nintedanib for immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with SMARCA4-mutant NSCLC: a case report. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
1342	Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity. <i>Clinical and Translational Oncology</i> , 2023, 25, 3073-3085.	1.2	2
1346	Case Report: Imaging immune checkpoint inhibitor-induced yin-yang effects in the brain. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1365	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians. <i>Drug Safety</i> , 2023, 46, 819-833.	1.4	2
1369	Arzneimittel- und MedizinproduktschÄden â€“ Begutachtung. <i>Springer Reference Medizin</i> , 2023, , 1-15.	0.0	0
1389	Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients. <i>International Review of Cell and Molecular Biology</i> , 2024, , 181-206.	1.6	0
1394	SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	3
1398	Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers. <i>Cancer Chemotherapy and Pharmacology</i> , 2023, 92, 165-179.	1.1	0
1427	Case report: a successful treatment with immune checkpoint inhibitors was associated with severe dermatologic toxicities in a patient with double primary malignancies. <i>Discover Oncology</i> , 2023, 14, .	0.8	1
1429	Nano-Biofortified Crop Plants with Zinc for Human Health. , 2023, , 53-76.		0
1435	Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1444	Role of echocardiography in patients treated with immune checkpoints inhibitors. <i>Journal of Echocardiography</i> , 0, , .	0.4	0
1450	è;ç~ç) ,ã...³çš,,ä,%oç°\$æ·ã·ç»“æž,,çš,,æ£€æµ«ã'CEé†âCE-â†æž. <i>Journal of Zhejiang University: Science B</i> , 2023, 24, 739-795. 1		
1455	Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion. <i>Advances in Therapy</i> , 2023, 40, 5579-5590.	1.3	0
1458	Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer. <i>Current Oncology</i> , 2023, 30, 7802-7809.	0.9	1

#	ARTICLE	IF	CITATIONS
1465	Encephalitis in a patient with hypopharynx cancer treated with immune checkpoint inhibitors and radiotherapy: a case report and review of the literature. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
1479	Cancer Among the Elderly. , 2023, , 1-31.		0
1499	Progress in systemic therapy for advanced-stage urothelial carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2024, 21, 8-27.	12.5	1
1509	Neoadjuvant Therapy in Locally Advanced Renal Cell Carcinoma. , 2023, , 195-229.		0
1529	Immune Checkpoint Inhibitors and Systemic Side Effects: Overview for the Inpatient Dermatologist. <i>Current Dermatology Reports</i> , 2023, 12, 225-232.	1.1	0
1538	Immune Checkpoint Inhibition. , 2024, , 1-91.		0
1540	Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report. <i>Cancer Chemotherapy and Pharmacology</i> , 0, , .	1.1	1
1544	Associations between HIFs and tumor immune checkpoints: mechanism and therapy. <i>Discover Oncology</i> , 2024, 15, .	0.8	1
1553	Antibody-Based Biotherapeutics in Cancer. , 2024, , 547-589.		0
1558	Immune checkpoint inhibitor-associated colitis in unresectable hepatocellular carcinoma: two cases of early onset after treatment with durvalumab plus tremelimumab. <i>Clinical Journal of Gastroenterology</i> , 2024, 17, 307-310.	0.4	0
1560	Rare Immune-Related Adverse Events (irAEs): Approach to Diagnosis and Management. <i>Pharmaceutical Medicine</i> , 2024, 38, 25-38.	1.0	0
1586	Value of 2-[18F]FDG-PET/CT in identifying immune-related adverse events in patients with melanoma or non-small cell lung cancer: a systematic scoping review. <i>Clinical and Translational Imaging</i> , 2024, 12, 187-195.	1.1	0
1593	Clinical and translational attributes of immune-related adverse events. <i>Nature Cancer</i> , 0, , .	5.7	0
1595	Case Report: Sudden very late-onset near fatal PD1 inhibitor-associated myocarditis with out-of-hospital cardiac arrest after >2.5 years of pembrolizumab treatment. <i>Frontiers in Cardiovascular Medicine</i> , 0, 11, .	1.1	0
1598	HÄmatologische Neoplasien und solide Tumore. , 2023, , 99-174.		0
1619	Neurologic manifestations of autoimmunity with immune checkpoint inhibitors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2024, , 449-465.	1.0	0